DDI-DrugBank.d481.s0|11-18|products|group
DDI-DrugBank.d481.s0|38-42|foods|group
DDI-DrugBank.d481.s0|47-51|drugs|group
DDI-DrugBank.d481.s0|82-86|EMCYT|brand
DDI-MedLine.d63.s0|13-19|actions|group
DDI-MedLine.d63.s0|111-124|beta-endorphin|group
DDI-MedLine.d63.s0|142-145|rats|group
DDI-MedLine.d63.s1|46-52|opioids|group
DDI-MedLine.d63.s1|83-87|sites|group
DDI-MedLine.d63.s1|114-120|effects|group
DDI-MedLine.d63.s1|180-186|systems|group
DDI-MedLine.d63.s2|144-157|beta-endorphin|group
DDI-MedLine.d63.s3|30-43|beta-endorphin|group
DDI-MedLine.d63.s3|120-127|stimulus|group
DDI-MedLine.d63.s3|132-135|rats|group
DDI-MedLine.d63.s4|37-41|doses|group
DDI-MedLine.d63.s4|56-65|micrograms|group
DDI-MedLine.d63.s4|184-197|beta-endorphin|group
DDI-MedLine.d63.s4|232-241|micrograms|group
DDI-MedLine.d63.s4|317-330|beta-endorphin|group
DDI-MedLine.d63.s4|336-345|micrograms|group
DDI-MedLine.d63.s5|48-57|micrograms|group
DDI-MedLine.d63.s5|158-167|micrograms|group
DDI-MedLine.d63.s6|42-46|doses|group
DDI-MedLine.d63.s6|61-70|micrograms|group
DDI-MedLine.d63.s6|173-186|beta-endorphin|group
DDI-MedLine.d63.s7|4-10|results|group
DDI-MedLine.d63.s7|109-122|beta-endorphin|group
DDI-MedLine.d63.s7|206-219|beta-endorphin|group
DDI-MedLine.d63.s7|263-269|actions|group
DDI-MedLine.d63.s7|330-336|systems|group
DDI-MedLine.d63.s8|26-32|systems|group
DDI-MedLine.d63.s8|38-51|beta-endorphin|group
DDI-DrugBank.d278.s0|0-9|Enoxaparin|drug
DDI-DrugBank.d278.s0|32-43|subcutaneous|group
DDI-DrugBank.d278.s0|69-73|doses|group
DDI-DrugBank.d278.s0|93-108|pharmacokinetics|group
DDI-DrugBank.d278.s0|174-179|adults|group
DDI-DrugBank.d5.s0|59-68|WELLBUTRIN|brand
DDI-DrugBank.d5.s0|118-122|drugs|group
DDI-DrugBank.d5.s0|187-196|WELLBUTRIN|brand
DDI-DrugBank.d5.s0|225-229|drugs|group
DDI-DrugBank.d5.s1|76-80|drugs|group
DDI-DrugBank.d5.s2|9-15|studies|group
DDI-DrugBank.d5.s2|93-98|CYP2B6|brand
DDI-DrugBank.d5.s3|25-30|exists|group
DDI-DrugBank.d5.s3|63-72|WELLBUTRIN|brand
DDI-DrugBank.d5.s3|78-82|drugs|group
DDI-DrugBank.d5.s3|100-105|CYP2B6|brand
DDI-DrugBank.d5.s4|102-111|isoenzymes|group
DDI-DrugBank.d5.s5|4-10|effects|group
DDI-DrugBank.d5.s5|63-78|pharmacokinetics|group
DDI-DrugBank.d5.s5|108-118|metabolites|group
DDI-DrugBank.d5.s5|158-167|volunteers|group
DDI-DrugBank.d5.s6|62-68|tablets|group
DDI-DrugBank.d5.s6|113-128|pharmacokinetics|group
DDI-DrugBank.d5.s7|32-40|increases|group
DDI-DrugBank.d5.s7|49-51|AUC|brand
DDI-DrugBank.d5.s7|57-60|Cmax|brand
DDI-DrugBank.d5.s7|93-100|moieties|group
DDI-DrugBank.d5.s8|42-46|drugs|group
DDI-DrugBank.d5.s8|109-121|phenobarbital|drug
DDI-DrugBank.d5.s9|76-82|enzymes|group
DDI-DrugBank.d5.s9|87-92|humans|group
DDI-DrugBank.d5.s10|70-74|times|group
DDI-DrugBank.d5.s10|100-109|volunteers|group
DDI-DrugBank.d5.s10|118-121|days|group
DDI-DrugBank.d5.s11|0-11|Nevertheless|group
DDI-DrugBank.d5.s11|66-76|alterations|group
DDI-DrugBank.d5.s11|87-92|levels|group
DDI-DrugBank.d5.s11|112-116|drugs|group
DDI-DrugBank.d5.s12|0-4|Drugs|group
DDI-DrugBank.d5.s12|6-16|Metabolized|brand
DDI-DrugBank.d5.s12|21-30|Cytochrome|brand
DDI-DrugBank.d5.s12|51-54|Many|brand
DDI-DrugBank.d5.s12|56-60|drugs|group
DDI-DrugBank.d5.s12|78-92|antidepressants|group
DDI-DrugBank.d5.s12|94-99|(SSRIs|group
DDI-DrugBank.d5.s12|107-116|tricyclics|group
DDI-DrugBank.d5.s12|120-132|beta-blockers|group
DDI-DrugBank.d5.s12|135-149|antiarrhythmics|group
DDI-DrugBank.d5.s12|156-169|antipsychotics|group
DDI-DrugBank.d5.s12|194-199|CYP2D6|brand
DDI-DrugBank.d5.s13|92-101|inhibitors|group
DDI-DrugBank.d5.s13|110-115|CYP2D6|brand
DDI-DrugBank.d5.s14|22-29|subjects|group
DDI-DrugBank.d5.s14|31-35|(ages|group
DDI-DrugBank.d5.s14|46-50|years|group
DDI-DrugBank.d5.s14|72-83|metabolizers|group
DDI-DrugBank.d5.s14|92-97|CYP2D6|brand
DDI-DrugBank.d5.s14|116-120|doses|group
DDI-DrugBank.d5.s14|198-208|desipramine|drug
DDI-DrugBank.d5.s14|224-227|Cmax|brand
DDI-DrugBank.d5.s14|230-232|AUC|brand
DDI-DrugBank.d5.s14|247-257|desipramine|drug
DDI-DrugBank.d5.s15|38-41|days|group
DDI-DrugBank.d5.s16|40-44|drugs|group
DDI-DrugBank.d5.s16|61-66|CYP2D6|brand
DDI-DrugBank.d5.s17|47-51|drugs|group
DDI-DrugBank.d5.s17|77-82|CYP2D6|brand
DDI-DrugBank.d5.s17|112-126|antidepressants|group
DDI-DrugBank.d5.s17|135-147|nortriptyline|drug
DDI-DrugBank.d5.s17|150-159|imipramine|drug
DDI-DrugBank.d5.s17|162-172|desipramine|drug
DDI-DrugBank.d5.s17|212-225|antipsychotics|group
DDI-DrugBank.d5.s17|247-257|risperidone|drug
DDI-DrugBank.d5.s17|275-287|beta-blockers|group
DDI-DrugBank.d5.s17|296-305|metoprolol|drug
DDI-DrugBank.d5.s17|313-316|Type|brand
DDI-DrugBank.d5.s17|321-335|antiarrhythmics|group
DDI-DrugBank.d5.s18|100-105|CYP2D6|brand
DDI-DrugBank.d5.s18|222-232|medications|group
DDI-DrugBank.d5.s19|4-13|Inhibitors|group
DDI-DrugBank.d5.s19|16-22|Studies|group
DDI-DrugBank.d5.s19|27-33|animals|group
DDI-DrugBank.d5.s19|103-105|MAO|brand
DDI-DrugBank.d5.s20|13-22|Amantadine|drug
DDI-DrugBank.d5.s20|25-31|Limited|brand
DDI-DrugBank.d5.s20|85-95|experiences|group
DDI-DrugBank.d5.s20|100-107|patients|group
DDI-DrugBank.d5.s20|166-175|amantadine|drug
DDI-DrugBank.d5.s21|18-27|WELLBUTRIN|brand
DDI-DrugBank.d5.s21|29-35|Tablets|group
DDI-DrugBank.d5.s21|40-47|patients|group
DDI-DrugBank.d5.s21|78-87|amantadine|drug
DDI-DrugBank.d5.s21|157-161|doses|group
DDI-DrugBank.d5.s21|186-194|increases|group
DDI-DrugBank.d5.s22|0-4|Drugs|group
DDI-DrugBank.d5.s22|11-15|Lower|brand
DDI-DrugBank.d5.s22|17-23|Seizure|brand
DDI-DrugBank.d5.s22|25-33|Threshold|brand
DDI-DrugBank.d5.s22|36-45|Concurrent|brand
DDI-DrugBank.d5.s22|65-74|WELLBUTRIN|brand
DDI-DrugBank.d5.s22|80-85|agents|group
DDI-DrugBank.d5.s22|94-107|antipsychotics|group
DDI-DrugBank.d5.s22|116-130|antidepressants|group
DDI-DrugBank.d5.s22|133-144|theophylline|drug
DDI-DrugBank.d5.s22|156-163|steroids|group
DDI-DrugBank.d5.s23|42-50|increases|group
DDI-DrugBank.d5.s24|9-19|Transdermal|brand
DDI-DrugBank.d5.s24|21-26|System|brand
DDI-DrugBank.d5.s25|60-66|reports|group
DDI-DrugBank.d5.s25|96-101|events|group
DDI-DrugBank.d5.s25|135-142|patients|group
DDI-DrugBank.d5.s25|192-201|WELLBUTRIN|brand
DDI-DrugBank.d5.s26|49-58|WELLBUTRIN|brand
DDI-DrugBank.d5.s26|128-144|CONTRAINDICATIONS|brand
DDI-DrugBank.d283.s0|5-18|Anticoagulants|group
DDI-DrugBank.d283.s0|20-26|CAUTION|brand
DDI-DrugBank.d283.s0|38-46|EXERCISED|brand
DDI-DrugBank.d283.s0|53-60|COUMARIN|brand
DDI-DrugBank.d283.s0|62-75|ANTICOAGULANTS|group
DDI-DrugBank.d283.s0|81-85|GIVEN|brand
DDI-DrugBank.d283.s0|90-100|CONJUNCTION|brand
DDI-DrugBank.d283.s0|107-112|TRICOR|brand
DDI-DrugBank.d283.s1|4-9|DOSAGE|brand
DDI-DrugBank.d283.s1|18-31|ANTICOAGULANTS|group
DDI-DrugBank.d283.s1|43-49|REDUCED|brand
DDI-DrugBank.d283.s1|54-61|MAINTAIN|brand
DDI-DrugBank.d283.s1|67-77|PROTHROMBIN|brand
DDI-DrugBank.d283.s1|79-86|TIME/INR|brand
DDI-DrugBank.d283.s1|95-101|DESIRED|brand
DDI-DrugBank.d283.s1|103-107|LEVEL|brand
DDI-DrugBank.d283.s1|112-118|PREVENT|brand
DDI-DrugBank.d283.s1|120-127|BLEEDING|brand
DDI-DrugBank.d283.s1|129-141|COMPLICATIONS|brand
DDI-DrugBank.d283.s2|9-19|PROTHROMBIN|brand
DDI-DrugBank.d283.s2|21-28|TIME/INR|brand
DDI-DrugBank.d283.s2|30-43|DETERMINATIONS|brand
DDI-DrugBank.d283.s2|49-57|ADVISABLE|brand
DDI-DrugBank.d283.s2|77-86|DEFINITELY|brand
DDI-DrugBank.d283.s2|88-97|DETERMINED|brand
DDI-DrugBank.d283.s2|108-118|PROTHROMBIN|brand
DDI-DrugBank.d283.s2|120-127|TIME/INR|brand
DDI-DrugBank.d283.s2|133-142|STABILIZED|brand
DDI-DrugBank.d283.s3|18-27|inhibitors|group
DDI-DrugBank.d283.s3|50-55|TRICOR|brand
DDI-DrugBank.d283.s3|61-67|HMG-CoA|brand
DDI-DrugBank.d283.s3|79-88|inhibitors|group
DDI-DrugBank.d283.s3|108-113|unless|group
DDI-DrugBank.d283.s3|138-148|alterations|group
DDI-DrugBank.d283.s3|159-164|levels|group
DDI-DrugBank.d283.s4|0-5|Resins|group
DDI-DrugBank.d283.s4|8-12|Since|brand
DDI-DrugBank.d283.s4|14-22|bile acid|drug
DDI-DrugBank.d283.s4|24-35|sequestrants|group
DDI-DrugBank.d283.s4|52-56|drugs|group
DDI-DrugBank.d283.s4|78-85|patients|group
DDI-DrugBank.d283.s4|99-104|TRICOR|brand
DDI-DrugBank.d283.s4|136-140|hours|group
DDI-DrugBank.d283.s4|150-158|bile acid|drug
DDI-DrugBank.d283.s5|67-75|decreases|group
DDI-DrugBank.d283.s5|105-109|rises|group
DDI-DrugBank.d283.s5|204-208|drugs|group
DDI-DrugBank.d283.s5|220-225|TRICOR|brand
DDI-DrugBank.d283.s6|4-11|benefits|group
DDI-DrugBank.d283.s6|17-21|risks|group
DDI-DrugBank.d283.s6|32-37|TRICOR|brand
DDI-DrugBank.d283.s6|44-61|immunosuppressants|group
DDI-DrugBank.d283.s6|97-102|agents|group
DDI-DrugBank.d283.s8|10-21|interactions|group
DDI-DrugBank.d283.s8|32-38|studies|group
DDI-DrugBank.d283.s8|58-67|microsomes|group
DDI-DrugBank.d283.s8|99-113|fenofibric acid|drug
DDI-DrugBank.d283.s8|123-132|inhibitors|group
DDI-DrugBank.d283.s8|159-166|isoforms|group
DDI-DrugBank.d283.s8|176-181|CYP2D6|brand
DDI-DrugBank.d283.s8|184-189|CYP2E1|brand
DDI-DrugBank.d283.s8|195-200|CYP1A2|brand
DDI-DrugBank.d283.s9|14-23|inhibitors|group
DDI-DrugBank.d283.s9|28-34|CYP2C19|brand
DDI-DrugBank.d283.s9|40-45|CYP2A6|brand
DDI-DrugBank.d283.s9|69-78|inhibitors|group
DDI-DrugBank.d283.s9|83-88|CYP2C9|brand
DDI-DrugBank.d283.s9|105-118|concentrations|group
DDI-DrugBank.d283.s10|30-43|anticoagulants|group
DDI-DrugBank.d283.s11|0-8|Bile acid|drug
DDI-DrugBank.d283.s11|10-21|sequestrants|group
DDI-DrugBank.d283.s11|53-57|drugs|group
DDI-DrugBank.d283.s12|69-73|hours|group
DDI-DrugBank.d283.s12|83-91|bile acid|drug
DDI-DrugBank.d283.s13|63-68|TRICOR|brand
DDI-DrugBank.d283.s13|76-86|pravastatin|drug
DDI-DrugBank.d283.s13|114-117|days|group
DDI-DrugBank.d283.s13|155-158|Cmax|brand
DDI-DrugBank.d283.s13|164-166|AUC|brand
DDI-DrugBank.d283.s13|168-173|values|group
DDI-DrugBank.d283.s13|179-189|pravastatin|drug
DDI-DrugBank.d283.s13|317-340|-hydroxy-iso-pravastatin|drug
DDI-DrugBank.d283.s13|471-476|adults|group
DDI-DrugBank.d283.s14|17-27|pravastatin|drug
DDI-DrugBank.d283.s14|71-86|pharmacokinetics|group
DDI-DrugBank.d283.s14|91-105|fenofibric acid|drug
DDI-DrugBank.d283.s15|64-69|TRICOR|brand
DDI-DrugBank.d283.s15|77-88|atorvastatin|drug
DDI-DrugBank.d283.s15|116-119|days|group
DDI-DrugBank.d283.s15|205-216|atorvastatin|drug
DDI-DrugBank.d283.s15|218-220|AUC|brand
DDI-DrugBank.d283.s15|222-227|values|group
DDI-DrugBank.d283.s15|243-247|males|group
DDI-DrugBank.d283.s16|4-15|atorvastatin|drug
DDI-DrugBank.d283.s16|17-20|Cmax|brand
DDI-DrugBank.d283.s16|22-27|values|group
DDI-DrugBank.d283.s17|4-19|pharmacokinetics|group
DDI-DrugBank.d283.s17|24-38|fenofibric acid|drug
DDI-DrugBank.d283.s17|75-86|atorvastatin|drug
DDI-DrugBank.d78.s0|0-7|Antacids|group
DDI-DrugBank.d78.s0|10-19|Sucralfate|brand
DDI-DrugBank.d78.s0|22-26|Metal|brand
DDI-DrugBank.d78.s0|28-34|Cations|group
DDI-DrugBank.d78.s0|37-49|Multivitamins|group
DDI-DrugBank.d78.s0|51-60|Quinolones|drug
DDI-DrugBank.d78.s0|67-74|chelates|group
DDI-DrugBank.d78.s0|117-123|cations|group
DDI-DrugBank.d78.s1|18-27|quinolones|drug
DDI-DrugBank.d78.s1|34-41|antacids|group
DDI-DrugBank.d78.s1|115-121|cations|group
DDI-DrugBank.d78.s1|131-134|iron|drug_n
DDI-DrugBank.d78.s1|145-157|multivitamins|group
DDI-DrugBank.d78.s1|170-173|iron|drug_n
DDI-DrugBank.d78.s1|192-203|formulations|group
DDI-DrugBank.d78.s1|239-245|cations|group
DDI-DrugBank.d78.s1|255-259|VIDEX|brand
DDI-DrugBank.d78.s1|292-298|tablets|group
DDI-DrugBank.d78.s1|347-359|substantially|group
DDI-DrugBank.d78.s1|394-403|quinolones|drug
DDI-DrugBank.d78.s1|428-441|concentrations|group
DDI-DrugBank.d78.s2|6-11|agents|group
DDI-DrugBank.d78.s2|42-46|hours|group
DDI-DrugBank.d78.s2|60-64|hours|group
DDI-DrugBank.d78.s2|72-84|grepafloxacin|drug
DDI-DrugBank.d78.s3|9-19|Theobromine|brand
DDI-DrugBank.d78.s3|21-33|Grepafloxacin|drug
DDI-DrugBank.d78.s3|47-56|quinolones|drug
DDI-DrugBank.d78.s4|6-15|stimulants|group
DDI-DrugBank.d78.s5|8-15|patients|group
DDI-DrugBank.d78.s5|101-107|effects|group
DDI-DrugBank.d78.s6|0-11|Theophylline|drug
DDI-DrugBank.d78.s6|14-26|Grepafloxacin|drug
DDI-DrugBank.d78.s6|76-87|theophylline|drug
DDI-DrugBank.d78.s7|6-17|theophylline|drug
DDI-DrugBank.d78.s7|19-32|concentrations|group
DDI-DrugBank.d78.s7|48-60|grepafloxacin|drug
DDI-DrugBank.d78.s7|102-113|theophylline|drug
DDI-DrugBank.d78.s8|38-50|grepafloxacin|drug
DDI-DrugBank.d78.s8|79-90|theophylline|drug
DDI-DrugBank.d78.s8|97-108|theophylline|drug
DDI-DrugBank.d78.s8|180-192|grepafloxacin|drug
DDI-DrugBank.d78.s8|218-229|theophylline|drug
DDI-DrugBank.d78.s8|231-244|concentrations|group
DDI-DrugBank.d78.s8|295-305|adjustments|group
DDI-DrugBank.d78.s9|13-20|subjects|group
DDI-DrugBank.d78.s9|99-111|grepafloxacin|drug
DDI-DrugBank.d78.s10|22-31|quinolones|drug
DDI-DrugBank.d78.s10|67-73|effects|group
DDI-DrugBank.d78.s10|94-104|derivatives|group
DDI-DrugBank.d78.s10|142-156|anticoagulation|group
DDI-DrugBank.d78.s10|196-204|quinolone|drug
DDI-DrugBank.d78.s10|206-218|antimicrobial|group
DDI-DrugBank.d78.s10|257-267|derivatives|group
DDI-DrugBank.d78.s11|0-4|Drugs|group
DDI-DrugBank.d78.s11|6-16|Metabolized|brand
DDI-DrugBank.d78.s11|21-30|Cytochrome|brand
DDI-DrugBank.d78.s11|37-43|Enzymes|group
DDI-DrugBank.d78.s11|97-109|grepafloxacin|drug
DDI-DrugBank.d78.s11|114-125|theophylline|drug
DDI-DrugBank.d78.s11|127-135|indicates|group
DDI-DrugBank.d78.s11|142-154|grepafloxacin|drug
DDI-DrugBank.d78.s11|156-163|inhibits|group
DDI-DrugBank.d78.s11|165-176|theophylline|drug
DDI-DrugBank.d78.s11|211-216|CYP1A2|brand
DDI-DrugBank.d78.s12|18-24|studies|group
DDI-DrugBank.d78.s12|72-84|grepafloxacin|drug
DDI-DrugBank.d78.s12|107-111|C.P.A|brand
DDI-DrugBank.d78.s13|0-9|substrates|group
DDI-DrugBank.d78.s13|42-48|effects|group
DDI-DrugBank.d78.s13|53-65|grepafloxacin|drug
DDI-DrugBank.d78.s13|101-112|theophylline|drug
DDI-DrugBank.d78.s14|19-28|quinolones|drug
DDI-DrugBank.d78.s15|6-10|drugs|group
DDI-DrugBank.d78.s15|27-31|C.P.A|brand
DDI-DrugBank.d78.s16|44-52|midazolam|drug
DDI-DrugBank.d78.s16|59-67|triazolam|drug
DDI-DrugBank.d78.s17|50-62|grepafloxacin|drug
DDI-DrugBank.d78.s17|85-90|C.P.A.|brand
DDI-DrugBank.d78.s17|92-101|substrates|group
DDI-DrugBank.d78.s18|0-7|Patients|group
DDI-DrugBank.d78.s18|48-57|substrates|group
DDI-DrugBank.d78.s18|62-67|C.P.A.|brand
DDI-DrugBank.d78.s18|101-106|trials|group
DDI-DrugBank.d78.s18|111-123|grepafloxacin|drug
DDI-DrugBank.d78.s19|13-29|Anti-inflammatory|group
DDI-DrugBank.d78.s19|31-35|Drugs|group
DDI-DrugBank.d78.s19|37-43|(NSAIDs|group
DDI-DrugBank.d78.s19|96-99|anti|group
DDI-DrugBank.d78.s19|126-134|quinolone|drug
DDI-DrugBank.d78.s19|153-157|risks|group
DDI-DrugBank.d78.s19|162-164|CNS|brand
DDI-DrugBank.d78.s19|182-192|convulsions|group
DDI-DrugBank.d78.s20|0-11|Antidiabetic|group
DDI-DrugBank.d78.s20|13-18|Agents|group
DDI-DrugBank.d78.s20|21-32|Disturbances|group
DDI-DrugBank.d78.s20|116-123|patients|group
DDI-DrugBank.d78.s20|152-161|quinolones|drug
DDI-DrugBank.d78.s20|170-181|antidiabetic|group
DDI-DrugBank.d78.s21|73-78|agents|group
DDI-DrugBank.d176.s0|0-8|Diuretics|group
DDI-DrugBank.d176.s0|11-18|Patients|group
DDI-DrugBank.d176.s0|23-31|diuretics|group
DDI-DrugBank.d176.s0|190-199|fosinopril|drug
DDI-DrugBank.d176.s1|31-37|effects|group
DDI-DrugBank.d176.s1|157-166|fosinopril|drug
DDI-DrugBank.d176.s2|116-120|hours|group
DDI-DrugBank.d176.s2|193-198|DOSAGE|brand
DDI-DrugBank.d176.s2|204-218|ADMINISTRATION.|brand
DDI-DrugBank.d176.s3|10-20|Supplements|group
DDI-DrugBank.d176.s3|26-42|Potassium-Sparing|drug
DDI-DrugBank.d176.s3|44-52|Diuretics|group
DDI-DrugBank.d176.s3|55-64|Fosinopril|drug
DDI-DrugBank.d176.s3|97-100|loss|group
DDI-DrugBank.d176.s3|112-119|thiazide|drug
DDI-DrugBank.d176.s3|121-129|diuretics|group
DDI-DrugBank.d176.s4|0-16|Potassium-sparing|drug
DDI-DrugBank.d176.s4|18-26|diuretics|group
DDI-DrugBank.d176.s4|28-42|(spironolactone|drug_n
DDI-DrugBank.d176.s4|72-77|others|group
DDI-DrugBank.d176.s4|93-103|supplements|group
DDI-DrugBank.d176.s5|38-43|agents|group
DDI-DrugBank.d176.s5|102-109|patients|group
DDI-DrugBank.d176.s6|9-17|Increased|brand
DDI-DrugBank.d176.s6|33-38|levels|group
DDI-DrugBank.d176.s6|44-51|symptoms|group
DDI-DrugBank.d176.s6|95-102|patients|group
DDI-DrugBank.d176.s6|114-116|ACE|brand
DDI-DrugBank.d176.s6|118-127|inhibitors|group
DDI-DrugBank.d176.s7|6-10|drugs|group
DDI-DrugBank.d176.s7|92-97|levels|group
DDI-DrugBank.d176.s9|0-7|Antacids|group
DDI-DrugBank.d176.s9|139-148|fosinopril|drug
DDI-DrugBank.d176.s9|164-169|levels|group
DDI-DrugBank.d176.s9|196-207|fosinoprilat|drug
DDI-DrugBank.d176.s9|226-235|fosinopril|drug
DDI-DrugBank.d176.s9|273-280|antacids|group
DDI-DrugBank.d176.s9|307-316|fosinopril|drug
DDI-DrugBank.d176.s10|50-55|agents|group
DDI-DrugBank.d176.s10|103-107|hours|group
DDI-DrugBank.d176.s11|7-13|Neither|brand
DDI-DrugBank.d176.s11|15-24|fosinopril|drug
DDI-DrugBank.d176.s11|41-51|metabolites|group
DDI-DrugBank.d176.s12|64-70|studies|group
DDI-DrugBank.d176.s12|93-102|nifedipine|drug
DDI-DrugBank.d176.s12|105-114|propanolol|drug
DDI-DrugBank.d176.s12|117-135|hydrochlorothiazide|drug
DDI-DrugBank.d176.s12|227-238|fosinoprilat|drug
DDI-DrugBank.d176.s12|279-288|fosinopril|drug
DDI-DrugBank.d176.s12|312-316|drugs|group
DDI-DrugBank.d176.s13|58-67|fosinopril|drug
DDI-DrugBank.d176.s13|108-119|fosinoprilat|drug
DDI-DrugBank.d176.s14|70-79|parameters|group
DDI-DrugBank.d176.s14|121-133|anticoagulant|group
DDI-DrugBank.d176.s15|16-19|Test|brand
DDI-DrugBank.d176.s15|21-31|Interaction|brand
DDI-DrugBank.d176.s15|33-42|Fosinopril|drug
DDI-DrugBank.d176.s15|95-100|levels|group
DDI-DrugBank.d176.s15|111-115|Digi-|brand
DDI-DrugBank.d176.s15|117-119|Tab|brand
DDI-DrugBank.d176.s15|122-124|RIA|brand
DDI-DrugBank.d176.s15|126-128|Kit|brand
DDI-DrugBank.d176.s15|134-140|Digoxin|brand
DDI-DrugBank.d176.s16|6-9|kits|group
DDI-DrugBank.d176.s16|24-35|Coat-A-Count|brand
DDI-DrugBank.d176.s16|38-40|RIA|brand
DDI-DrugBank.d176.s16|42-44|Kit|brand
DDI-DrugBank.d453.s0|78-87|antifungal|group
DDI-DrugBank.d453.s1|0-4|Drugs|group
DDI-DrugBank.d453.s2|16-19|Test|brand
DDI-DrugBank.d453.s2|21-32|Interactions|group
DDI-DrugBank.d453.s2|35-45|Measurement|brand
DDI-DrugBank.d453.s2|67-72|levels|group
DDI-DrugBank.d453.s2|102-106|Jaffe|brand
DDI-DrugBank.d453.s2|124-130|Ancobon|brand
DDI-DrugBank.d453.s2|188-193|values|group
DDI-DrugBank.d453.s3|55-59|makes|group
DDI-DrugBank.d453.s3|72-76|Jaffe|brand
DDI-MedLine.d121.s0|0-11|[Hippocampus|group
DDI-MedLine.d121.s0|28-32|sites|group
DDI-MedLine.d121.s0|87-94|theories|group
DDI-MedLine.d121.s0|127-131|forms|group
DDI-MedLine.d121.s0|180-186|systems|group
DDI-MedLine.d121.s0|207-221|characteristics|group
DDI-MedLine.d121.s1|0-6|Animals|group
DDI-MedLine.d121.s1|8-14|studies|group
DDI-MedLine.d121.s1|23-29|various|group
DDI-MedLine.d121.s1|43-50|theories|group
DDI-MedLine.d121.s1|88-92|basis|group
DDI-MedLine.d121.s2|35-41|aspects|group
DDI-MedLine.d121.s2|100-106|lesions|group
DDI-MedLine.d121.s3|27-35|instances|group
DDI-MedLine.d121.s3|87-93|lesions|group
DDI-MedLine.d121.s4|29-33|tasks|group
DDI-MedLine.d121.s4|71-77|lesions|group
DDI-MedLine.d121.s4|99-110|nevertheless|group
DDI-MedLine.d121.s4|134-141|subjects|group
DDI-MedLine.d121.s4|174-184|alterations|group
DDI-MedLine.d121.s4|193-203|hippocampus|group
DDI-MedLine.d121.s5|51-55|tasks|group
DDI-MedLine.d121.s5|68-76|bar-press|group
DDI-MedLine.d121.s6|0-6|Results|group
DDI-MedLine.d121.s7|40-50|alterations|group
DDI-MedLine.d121.s7|110-119|directions|group
DDI-MedLine.d121.s8|14-21|previous|group
DDI-MedLine.d121.s8|23-30|findings|group
DDI-MedLine.d121.s8|39-45|results|group
DDI-MedLine.d121.s8|64-74|hippocampus|group
DDI-MedLine.d121.s10|0-4|forms|group
DDI-MedLine.d121.s11|76-86|alterations|group
DDI-MedLine.d121.s11|157-163|systems|group
DDI-MedLine.d121.s12|0-3|Thus|group
DDI-MedLine.d121.s12|66-74|functions|group
DDI-MedLine.d121.s12|100-110|hippocampus|group
DDI-MedLine.d121.s12|249-257|TRUNCATED|brand
DDI-MedLine.d121.s12|266-270|WORDS|brand
DDI-DrugBank.d455.s0|9-15|studies|group
DDI-DrugBank.d455.s0|26-28|CYP|brand
DDI-DrugBank.d455.s0|30-36|enzymes|group
DDI-DrugBank.d455.s0|75-77|CYP|brand
DDI-DrugBank.d455.s0|79-85|enzymes|group
DDI-DrugBank.d455.s0|142-155|concentrations|group
DDI-DrugBank.d455.s1|20-27|achieves|group
DDI-DrugBank.d455.s2|6-12|enzymes|group
DDI-DrugBank.d455.s3|8-14|Binding|brand
DDI-DrugBank.d455.s3|17-26|Entacapone|brand
DDI-DrugBank.d455.s4|9-15|studies|group
DDI-DrugBank.d455.s4|94-98|drugs|group
DDI-DrugBank.d455.s4|119-132|salicylic acid|drug
DDI-DrugBank.d455.s4|155-162|diazepam|drug
DDI-DrugBank.d455.s5|0-4|Drugs|group
DDI-DrugBank.d455.s5|6-16|Metabolized|brand
DDI-DrugBank.d455.s5|21-48|Catechol-O-methyltransferase|brand
DDI-DrugBank.d455.s5|58-64|Hormone|brand
DDI-DrugBank.d455.s5|66-71|levels|group
DDI-DrugBank.d455.s5|74-81|Levodopa|brand
DDI-DrugBank.d455.s5|95-101|depress|group
DDI-DrugBank.d455.s5|151-156|levels|group
DDI-DrugBank.d455.s6|106-112|effects|group
DDI-DrugBank.d455.s7|34-38|MAO-B|brand
DDI-DrugBank.d455.s7|94-100|studies|group
DDI-DrugBank.d455.s8|14-23|Parkinsons|group
DDI-DrugBank.d455.s8|33-40|patients|group
DDI-DrugBank.d455.s8|54-59|trials|group
DDI-DrugBank.d455.s9|79-83|drugs|group
DDI-DrugBank.d455.s9|160-177|beta-glucuronidase|group
DDI-DrugBank.d455.s10|51-61|antibiotics|group
DDI-DrugBank.d455.s10|69-80|erythromycin|drug
DDI-DrugBank.d455.s11|34-47|antidepressant|group
DDI-DrugBank.d455.s11|49-58|imipramine|drug
DDI-DrugBank.d454.s0|2-11|Lofexidine|brand
DDI-DrugBank.d454.s0|29-31|CNS|brand
DDI-DrugBank.d454.s0|44-50|effects|group
DDI-DrugBank.d454.s0|64-75|barbiturates|group
DDI-DrugBank.d454.s0|87-95|sedatives|group
DDI-DrugBank.d454.s2|2-11|Lofexidine|brand
DDI-DrugBank.d454.s2|29-35|effects|group
DDI-DrugBank.d454.s2|40-56|anti-hypertensive|group
DDI-DrugBank.d454.s4|2-12|Concomitant|brand
DDI-DrugBank.d454.s4|31-45|antidepressants|group
DDI-DrugBank.d69.s0|7-16|Cerubidine|brand
DDI-DrugBank.d69.s0|59-69|doxorubicin|drug
DDI-DrugBank.d69.s0|71-79|increases|group
DDI-DrugBank.d69.s1|33-40|patients|group
DDI-DrugBank.d69.s1|106-110|doses|group
DDI-DrugBank.d69.s1|115-125|doxorubicin|drug
DDI-DrugBank.d69.s1|130-139|Cerubidine|brand
DDI-DrugBank.d69.s2|40-49|Cerubidine|brand
DDI-DrugBank.d69.s3|20-29|Cerubidine|brand
DDI-DrugBank.d69.s3|98-103|agents|group
DDI-DrugBank.d69.s4|12-22|medications|group
DDI-MedLine.d30.s0|27-33|effects|group
DDI-MedLine.d30.s0|38-57|N-allylnormetazocine|brand
DDI-MedLine.d30.s0|62-68|pigeons|group
DDI-MedLine.d30.s0|83-89|monkeys|group
DDI-MedLine.d30.s1|15-21|effects|group
DDI-MedLine.d30.s1|30-42|stereoisomers|group
DDI-MedLine.d30.s1|47-66|N-allylnormetazocine|brand
DDI-MedLine.d30.s1|68-72|(NANM|drug_n
DDI-MedLine.d30.s1|117-120|(PCP|drug_n
DDI-MedLine.d30.s1|126-132|pigeons|group
DDI-MedLine.d30.s1|147-153|monkeys|group
DDI-MedLine.d30.s1|214-215|FR|brand
DDI-MedLine.d30.s2|13-17|doses|group
DDI-MedLine.d30.s2|22-29|(+)-NANM|drug_n
DDI-MedLine.d30.s2|34-36|PCP|drug_n
DDI-MedLine.d30.s2|57-65|increases|group
DDI-MedLine.d30.s2|70-71|FI|brand
DDI-MedLine.d30.s2|87-93|monkeys|group
DDI-MedLine.d30.s2|109-117|increases|group
DDI-MedLine.d30.s2|122-123|FI|brand
DDI-MedLine.d30.s2|139-145|pigeons|group
DDI-MedLine.d30.s3|7-11|doses|group
DDI-MedLine.d30.s3|23-24|FI|brand
DDI-MedLine.d30.s3|30-31|FR|brand
DDI-MedLine.d30.s3|52-58|species|group
DDI-MedLine.d30.s4|19-28|enantiomer|group
DDI-MedLine.d30.s4|31-38|(-)-NANM|drug_n
DDI-MedLine.d30.s4|59-60|FI|brand
DDI-MedLine.d30.s4|97-103|species|group
DDI-MedLine.d30.s5|8-12|doses|group
DDI-MedLine.d30.s5|15-22|(-)-NANM|drug_n
DDI-MedLine.d30.s5|34-35|FI|brand
DDI-MedLine.d30.s5|41-42|FR|brand
DDI-MedLine.d30.s6|3-9|monkeys|group
DDI-MedLine.d30.s6|12-19|(-)-NANM|drug_n
DDI-MedLine.d30.s6|34-38|times|group
DDI-MedLine.d30.s6|57-64|(+)-NANM|drug_n
DDI-MedLine.d30.s6|92-98|whereas|group
DDI-MedLine.d30.s6|103-109|pigeons|group
DDI-MedLine.d30.s6|111-118|(-)-NANM|drug_n
DDI-MedLine.d30.s6|146-153|(+)-NANM|drug_n
DDI-MedLine.d30.s7|8-14|species|group
DDI-MedLine.d30.s7|17-24|(-)-NANM|drug_n
DDI-MedLine.d30.s7|35-42|(+)-NANM|drug_n
DDI-MedLine.d30.s7|77-83|effects|group
DDI-MedLine.d30.s7|100-101|FI|brand
DDI-MedLine.d30.s7|107-108|FR|brand
DDI-MedLine.d30.s8|3-9|monkeys|group
DDI-MedLine.d30.s8|16-22|effects|group
DDI-MedLine.d30.s8|27-34|(-)-NANM|drug_n
DDI-MedLine.d30.s8|45-52|(+)-NANM|drug_n
DDI-MedLine.d30.s8|57-59|PCP|drug_n
DDI-MedLine.d30.s9|4-8|doses|group
DDI-MedLine.d30.s9|49-55|effects|group
DDI-MedLine.d30.s9|60-67|(-)-NANM|drug_n
DDI-MedLine.d30.s9|88-92|times|group
DDI-MedLine.d30.s9|139-145|effects|group
DDI-MedLine.d30.s10|3-9|pigeons|group
DDI-MedLine.d30.s10|54-60|effects|group
DDI-MedLine.d30.s10|65-72|(-)-NANM|drug_n
DDI-MedLine.d30.s10|75-82|(+)-NANM|drug_n
DDI-MedLine.d30.s10|87-89|PCP|drug_n
DDI-MedLine.d30.s11|38-46|increases|group
DDI-MedLine.d30.s11|51-52|FI|brand
DDI-MedLine.d30.s11|90-94|doses|group
DDI-MedLine.d30.s11|106-113|(+)-NANM|drug_n
DDI-MedLine.d30.s11|118-120|PCP|drug_n
DDI-MedLine.d30.s11|125-131|pigeons|group
DDI-MedLine.d30.s11|161-169|decreases|group
DDI-MedLine.d30.s11|174-175|FI|brand
DDI-MedLine.d30.s11|180-181|FR|brand
DDI-MedLine.d30.s11|211-215|doses|group
DDI-MedLine.d30.s11|220-222|PCP|drug_n
DDI-MedLine.d30.s11|250-253|NANM|drug_n
DDI-MedLine.d30.s12|4-10|results|group
DDI-MedLine.d30.s12|77-83|effects|group
DDI-MedLine.d30.s12|88-91|NANM|drug_n
DDI-MedLine.d30.s13|69-75|effects|group
DDI-MedLine.d30.s13|80-86|pigeons|group
DDI-MedLine.d30.s13|124-130|effects|group
DDI-MedLine.d30.s13|135-141|monkeys|group
DDI-MedLine.d30.s14|50-56|effects|group
DDI-MedLine.d30.s14|78-80|PCP|drug_n
DDI-MedLine.d30.s14|90-96|species|group
DDI-DrugBank.d273.s0|10-21|Interactions|group
DDI-DrugBank.d273.s0|64-75|interactions|group
DDI-DrugBank.d273.s0|85-93|UROXATRAL|brand
DDI-DrugBank.d273.s0|105-118|alpha-blockers|group
DDI-DrugBank.d273.s1|9-20|interactions|group
DDI-DrugBank.d273.s1|43-51|UROXATRAL|brand
DDI-DrugBank.d273.s1|98-111|alpha-blockers|group
DDI-DrugBank.d363.s0|34-45|interactions|group
DDI-DrugBank.d363.s0|80-84|drugs|group
DDI-DrugBank.d363.s0|90-94|drugs|group
DDI-DrugBank.d363.s0|127-135|relaxants|group
DDI-DrugBank.d363.s0|138-148|intravenous|group
DDI-DrugBank.d363.s0|150-155|agents|group
DDI-DrugBank.d363.s0|179-184|agents|group
DDI-DrugBank.d363.s0|213-218|trials|group
DDI-DrugBank.d363.s1|53-57|drugs|group
DDI-DrugBank.d363.s2|37-46|predispose|drug
DDI-DrugBank.d363.s2|73-83|arrhythmias|group
DDI-DrugBank.d98.s0|0-11|Interactions|group
DDI-DrugBank.d98.s0|17-25|vitamin D|group
DDI-DrugBank.d98.s0|27-35|analogues|group
DDI-DrugBank.d98.s0|46-47|D2|brand
DDI-DrugBank.d98.s0|50-59|Vitamin D3|group
DDI-DrugBank.d98.s0|62-71|Calcitriol|brand
DDI-DrugBank.d98.s0|78-86|Calcidiol|brand
DDI-DrugBank.d98.s0|90-103|Cholestyramine|brand
DDI-DrugBank.d98.s0|106-119|Cholestyramine|brand
DDI-DrugBank.d98.s0|186-193|vitamins|group
DDI-DrugBank.d98.s1|54-63|vitamin D.|group
DDI-DrugBank.d98.s2|0-22|Phenytoin/Phenobarbital|drug
DDI-DrugBank.d98.s2|62-74|phenobarbital|drug
DDI-DrugBank.d98.s2|99-112|concentrations|group
DDI-DrugBank.d98.s2|117-125|vitamin D|group
DDI-DrugBank.d98.s2|143-152|endogenous|group
DDI-DrugBank.d98.s2|161-166|levels|group
DDI-DrugBank.d98.s3|71-75|doses|group
DDI-DrugBank.d98.s3|80-88|Rocaltrol|brand
DDI-DrugBank.d98.s3|116-120|drugs|group
DDI-DrugBank.d98.s4|0-8|Thiazides|group
DDI-DrugBank.d98.s4|11-19|Thiazides|group
DDI-DrugBank.d98.s5|5-11|reports|group
DDI-DrugBank.d98.s5|63-71|thiazides|drug
DDI-DrugBank.d98.s5|78-86|vitamin D|group
DDI-DrugBank.d98.s5|88-93|causes|group
DDI-DrugBank.d98.s7|0-8|Digitalis|group
DDI-DrugBank.d98.s7|11-19|Vitamin D|group
DDI-DrugBank.d98.s7|60-67|patients|group
DDI-DrugBank.d98.s7|95-103|digitalis|group
DDI-DrugBank.d98.s7|131-138|patients|group
DDI-DrugBank.d98.s7|164-174|arrhythmias|group
DDI-DrugBank.d98.s8|0-11|Ketoconazole|drug
DDI-DrugBank.d98.s8|14-25|Ketoconazole|drug
DDI-DrugBank.d98.s8|68-74|enzymes|group
DDI-DrugBank.d98.s8|79-88|vitamin D.|group
DDI-DrugBank.d98.s9|0-9|Reductions|group
DDI-DrugBank.d98.s9|20-29|endogenous|group
DDI-DrugBank.d98.s9|31-39|vitamin D|group
DDI-DrugBank.d98.s9|41-54|concentrations|group
DDI-DrugBank.d98.s9|133-144|ketoconazole|drug
DDI-DrugBank.d98.s10|34-40|studies|group
DDI-DrugBank.d98.s10|45-56|ketoconazole|drug
DDI-DrugBank.d98.s10|63-71|vitamin D|group
DDI-DrugBank.d98.s11|0-14|Corticosteroids|group
DDI-DrugBank.d98.s11|57-62|exists|group
DDI-DrugBank.d98.s11|72-80|vitamin D|group
DDI-DrugBank.d98.s11|82-90|analogues|group
DDI-DrugBank.d98.s11|131-145|corticosteroids|group
DDI-DrugBank.d98.s12|18-23|Agents|group
DDI-DrugBank.d98.s12|26-30|Since|brand
DDI-DrugBank.d98.s12|32-40|vitamin D|group
DDI-DrugBank.d98.s12|102-108|kidneys|group
DDI-DrugBank.d98.s12|114-118|bones|group
DDI-DrugBank.d98.s12|153-158|agents|group
DDI-DrugBank.d98.s13|0-8|Vitamin D|group
DDI-DrugBank.d98.s13|46-54|vitamin D|group
DDI-DrugBank.d98.s13|56-64|analogues|group
DDI-DrugBank.d98.s13|123-129|effects|group
DDI-DrugBank.d98.s14|8-18|Supplements|group
DDI-DrugBank.d98.s14|21-32|Uncontrolled|brand
DDI-DrugBank.d98.s14|74-85|preparations|group
DDI-DrugBank.d98.s15|11-30|Magnesium-containing|brand
DDI-DrugBank.d98.s15|32-43|preparations|group
DDI-DrugBank.d98.s15|50-57|antacids|group
DDI-DrugBank.d98.s15|140-148|vitamin D|group
DDI-DrugBank.d98.s15|153-160|patients|group
DDI-DrugBank.d98.s15|179-186|dialysis|group
DDI-DrugBank.d161.s0|29-35|studies|group
DDI-DrugBank.d161.s1|23-38|pharmacokinetics|group
DDI-DrugBank.d161.s1|43-48|Gemzar|brand
DDI-DrugBank.d161.s1|84-87|Drug|brand
DDI-DrugBank.d161.s1|89-100|Interactions|group
DDI-DrugBank.d161.s1|108-115|CLINICAL|brand
DDI-DrugBank.d161.s1|117-128|PHARMACOLOGY|brand
DDI-DrugBank.d340.s0|0-9|Nelfinavir|drug
DDI-DrugBank.d340.s1|20-27|VIRACEPT|brand
DDI-DrugBank.d340.s1|33-37|drugs|group
DDI-DrugBank.d340.s1|109-116|blockers|group
DDI-DrugBank.d340.s1|150-163|concentrations|group
DDI-DrugBank.d340.s1|247-253|effects|group
DDI-DrugBank.d340.s2|0-9|Nelfinavir|drug
DDI-DrugBank.d340.s2|38-42|C.P.A|brand
DDI-DrugBank.d340.s3|20-27|VIRACEPT|brand
DDI-DrugBank.d340.s3|33-37|drugs|group
DDI-DrugBank.d340.s3|70-79|nelfinavir|drug
DDI-DrugBank.d340.s3|88-101|concentrations|group
DDI-DrugBank.d340.s4|20-27|VIRACEPT|brand
DDI-DrugBank.d340.s4|33-37|drugs|group
DDI-DrugBank.d340.s4|71-80|nelfinavir|drug
DDI-DrugBank.d340.s4|89-102|concentrations|group
DDI-DrugBank.d340.s5|25-32|profiles|group
DDI-DrugBank.d340.s5|63-74|interactions|group
DDI-DrugBank.d340.s5|101-108|VIRACEPT|brand
DDI-DrugBank.d340.s5|123-151|trimethoprim/sulfamethoxazole|drug
DDI-DrugBank.d340.s5|154-167|clarithromycin|drug
DDI-DrugBank.d340.s5|170-181|erythromycin|drug
DDI-DrugBank.d340.s5|184-195|itraconazole|drug
DDI-DrugBank.d340.s5|200-210|fluconazole|drug
DDI-DrugBank.d340.s6|0-4|Drugs|group
DDI-DrugBank.d340.s6|25-38|Coadministered|brand
DDI-DrugBank.d340.s6|45-52|VIRACEPT|brand
DDI-DrugBank.d340.s6|54-68|Antiarrhythmics|group
DDI-DrugBank.d340.s6|93-106|Antihistamines|group
DDI-DrugBank.d340.s6|133-144|Antimigraine|group
DDI-DrugBank.d340.s6|153-163|derivatives|group
DDI-DrugBank.d340.s6|165-181|Antimycobacterial|group
DDI-DrugBank.d340.s6|183-188|agents|group
DDI-DrugBank.d340.s6|200-214|Benzodiazepines|group
DDI-DrugBank.d340.s6|216-224|midazolam|drug
DDI-DrugBank.d340.s6|227-235|triazolam|drug
DDI-DrugBank.d340.s6|237-238|GI|brand
DDI-DrugBank.d340.s6|249-254|agents|group
DDI-DrugBank.d340.s7|0-4|Drugs|group
DDI-DrugBank.d340.s7|12-18|Require|brand
DDI-DrugBank.d340.s7|22-25|Dose|brand
DDI-DrugBank.d340.s7|27-35|Reduction|brand
DDI-DrugBank.d340.s7|42-54|Coadminstered|brand
DDI-DrugBank.d340.s7|61-68|VIRACEPT|brand
DDI-DrugBank.d340.s7|70-86|Antimycobacterial|group
DDI-DrugBank.d340.s7|88-93|agents|group
DDI-DrugBank.d340.s8|37-44|VIRACEPT|brand
DDI-DrugBank.d340.s8|84-93|nelfinavir|drug
DDI-DrugBank.d340.s8|102-115|concentrations|group
DDI-DrugBank.d340.s8|120-127|patients|group
DDI-DrugBank.d340.s8|142-147|agents|group
DDI-DrugBank.d340.s9|0-13|Antihistamines|group
DDI-DrugBank.d340.s10|13-26|Administration|brand
DDI-DrugBank.d340.s10|48-55|VIRACEPT|brand
DDI-DrugBank.d340.s11|11-18|VIRACEPT|brand
DDI-DrugBank.d340.s11|106-112|serious|group
DDI-DrugBank.d340.s11|146-156|arrhythmias|group
DDI-DrugBank.d340.s12|41-48|VIRACEPT|brand
DDI-DrugBank.d340.s13|0-7|Anti-HIV|group
DDI-DrugBank.d340.s13|9-16|Protease|brand
DDI-DrugBank.d340.s13|18-27|Inhibitors|group
DDI-DrugBank.d340.s14|0-8|Indinavir|drug
DDI-DrugBank.d340.s14|11-26|Coadministration|brand
DDI-DrugBank.d340.s14|31-39|indinavir|drug
DDI-DrugBank.d340.s14|46-53|VIRACEPT|brand
DDI-DrugBank.d340.s14|86-95|nelfinavir|drug
DDI-DrugBank.d340.s14|104-106|AUC|brand
DDI-DrugBank.d340.s14|130-138|indinavir|drug
DDI-DrugBank.d340.s14|147-149|A.C|brand
DDI-DrugBank.d340.s16|0-8|Ritonavir|drug
DDI-DrugBank.d340.s16|11-26|Coadministration|brand
DDI-DrugBank.d340.s16|31-39|ritonavir|drug
DDI-DrugBank.d340.s16|46-53|VIRACEPT|brand
DDI-DrugBank.d340.s16|86-95|nelfinavir|drug
DDI-DrugBank.d340.s16|104-106|AUC|brand
DDI-DrugBank.d340.s16|134-142|ritonavir|drug
DDI-DrugBank.d340.s16|151-153|A.C|brand
DDI-DrugBank.d340.s18|0-9|Saquinavir|drug
DDI-DrugBank.d340.s18|12-27|Coadministration|brand
DDI-DrugBank.d340.s18|32-41|saquinavir|drug
DDI-DrugBank.d340.s18|102-111|saquinavir|drug
DDI-DrugBank.d340.s18|126-133|VIRACEPT|brand
DDI-DrugBank.d340.s18|166-175|nelfinavir|drug
DDI-DrugBank.d340.s18|184-186|AUC|brand
DDI-DrugBank.d340.s18|213-222|saquinavir|drug
DDI-DrugBank.d340.s18|231-233|A.C|brand
DDI-DrugBank.d340.s19|28-37|saquinavir|drug
DDI-DrugBank.d340.s19|52-59|capsules|group
DDI-DrugBank.d340.s19|108-118|adjustments|group
DDI-DrugBank.d340.s21|0-9|Antifungal|group
DDI-DrugBank.d340.s21|11-16|Agents|group
DDI-DrugBank.d340.s22|0-11|Ketoconazole|drug
DDI-DrugBank.d340.s22|14-29|Coadministration|brand
DDI-DrugBank.d340.s22|34-45|ketoconazole|drug
DDI-DrugBank.d340.s22|52-59|VIRACEPT|brand
DDI-DrugBank.d340.s22|91-100|nelfinavir|drug
DDI-DrugBank.d340.s22|109-111|A.C|brand
DDI-DrugBank.d340.s23|92-103|ketoconazole|drug
DDI-DrugBank.d340.s23|109-116|VIRACEPT|brand
DDI-DrugBank.d340.s24|0-7|Anti-HIV|group
DDI-DrugBank.d340.s24|9-15|Reverse|brand
DDI-DrugBank.d340.s24|17-29|Transcriptase|brand
DDI-DrugBank.d340.s24|31-40|Inhibitors|group
DDI-DrugBank.d340.s26|11-20|nelfinavir|drug
DDI-DrugBank.d340.s26|89-93|hours|group
DDI-DrugBank.d340.s27|37-46|zidovudine|drug
DDI-DrugBank.d340.s27|69-76|VIRACEPT|brand
DDI-DrugBank.d340.s28|27-42|pharmacokinetics|group
DDI-DrugBank.d340.s28|77-84|VIRACEPT|brand
DDI-DrugBank.d340.s28|110-119|lamivudine|drug
DDI-DrugBank.d340.s28|124-132|stavudine|drug
DDI-DrugBank.d340.s29|0-16|Antimycobacterial|group
DDI-DrugBank.d340.s29|18-23|Agents|group
DDI-DrugBank.d340.s30|11-26|Coadministration|brand
DDI-DrugBank.d340.s30|45-52|VIRACEPT|brand
DDI-DrugBank.d340.s30|84-93|nelfinavir|drug
DDI-DrugBank.d340.s30|102-104|AUC|brand
DDI-DrugBank.d340.s30|146-148|A.C|brand
DDI-DrugBank.d340.s31|106-113|VIRACEPT|brand
DDI-DrugBank.d340.s32|10-25|Coadministration|brand
DDI-DrugBank.d340.s32|43-50|VIRACEPT|brand
DDI-DrugBank.d340.s32|83-92|nelfinavir|drug
DDI-DrugBank.d340.s32|101-103|A.C|brand
DDI-DrugBank.d340.s34|5-18|Contraceptives|group
DDI-DrugBank.d340.s35|8-16|Estradiol|brand
DDI-DrugBank.d340.s35|22-34|Norethindrone|brand
DDI-DrugBank.d340.s35|37-52|Coadministration|brand
DDI-DrugBank.d340.s35|57-64|VIRACEPT|brand
DDI-DrugBank.d340.s35|71-78|OVCON-35|brand
DDI-DrugBank.d340.s35|172-185|concentrations|group
DDI-DrugBank.d340.s36|38-45|measures|group
DDI-DrugBank.d340.s36|82-89|VIRACEPT|brand
DDI-DrugBank.d66.s0|23-33|Concomitant|brand
DDI-DrugBank.d66.s0|42-52|L-glutamine|brand
DDI-DrugBank.d66.s1|28-33|status|group
DDI-DrugBank.d66.s2|15-25|Concomitant|brand
DDI-DrugBank.d66.s2|34-44|L-glutamine|brand
DDI-DrugBank.d66.s3|27-37|L-glutamine|brand
DDI-DrugBank.d66.s3|46-50|grams|group
DDI-DrugBank.d66.s3|75-79|doses|group
DDI-DrugBank.d66.s3|87-91|times|group
DDI-DrugBank.d66.s5|79-91|effectiveness|group
DDI-DrugBank.d66.s5|109-119|L-glutamine|brand
DDI-DrugBank.d66.s5|146-154|mucositis|group
DDI-DrugBank.d66.s6|24-31|patients|group
DDI-DrugBank.d66.s6|84-91|symptoms|group
DDI-DrugBank.d66.s6|150-160|L-glutamine|brand
DDI-DrugBank.d66.s7|28-38|L-glutamine|brand
DDI-DrugBank.d66.s7|56-60|grams|group
DDI-DrugBank.d66.s7|68-72|times|group
DDI-DrugBank.d66.s7|90-94|hours|group
DDI-DrugBank.d66.s7|195-203|reactions|group
DDI-DrugBank.d140.s0|43-47|drugs|group
DDI-DrugBank.d140.s0|57-61|class|group
DDI-DrugBank.d140.s0|124-134|fibric acid|drug
DDI-DrugBank.d140.s0|136-146|derivatives|group
DDI-DrugBank.d140.s0|156-170|(nicotinic acid|drug
DDI-DrugBank.d140.s0|174-185|erythromycin|drug
DDI-DrugBank.d140.s0|194-204|antifungals|group
DDI-DrugBank.d140.s1|14-25|atorvastatin|drug
DDI-DrugBank.d140.s1|31-36|Maalox|brand
DDI-DrugBank.d140.s1|38-39|TC|brand
DDI-DrugBank.d140.s1|80-93|concentrations|group
DDI-DrugBank.d140.s1|98-109|atorvastatin|drug
DDI-DrugBank.d140.s2|9-13|LDL-C|brand
DDI-DrugBank.d140.s3|0-9|Antipyrine|group
DDI-DrugBank.d140.s3|20-31|atorvastatin|drug
DDI-DrugBank.d140.s3|53-68|pharmacokinetics|group
DDI-DrugBank.d140.s3|73-82|antipyrine|group
DDI-DrugBank.d140.s3|85-96|interactions|group
DDI-DrugBank.d140.s3|109-113|drugs|group
DDI-DrugBank.d140.s3|151-158|isozymes|group
DDI-DrugBank.d140.s4|12-17|Plasma|brand
DDI-DrugBank.d140.s4|19-32|concentrations|group
DDI-DrugBank.d140.s4|37-48|atorvastatin|drug
DDI-DrugBank.d140.s4|98-109|atorvastatin|drug
DDI-DrugBank.d140.s5|9-13|LDL-C|brand
DDI-DrugBank.d140.s5|42-53|atorvastatin|drug
DDI-DrugBank.d140.s6|12-23|Atorvastatin|drug
DDI-DrugBank.d140.s6|32-45|concentrations|group
DDI-DrugBank.d140.s6|51-55|LDL-C|brand
DDI-DrugBank.d140.s7|23-27|doses|group
DDI-DrugBank.d140.s7|32-43|atorvastatin|drug
DDI-DrugBank.d140.s7|106-119|concentrations|group
DDI-DrugBank.d140.s8|0-7|Patients|group
DDI-DrugBank.d140.s9|0-11|Erythromycin|drug
DDI-DrugBank.d140.s9|25-35|individuals|group
DDI-DrugBank.d140.s9|45-58|concentrations|group
DDI-DrugBank.d140.s9|63-74|atorvastatin|drug
DDI-DrugBank.d140.s9|129-140|atorvastatin|drug
DDI-DrugBank.d140.s9|146-157|erythromycin|drug
DDI-DrugBank.d140.s10|5-18|Contraceptives|group
DDI-DrugBank.d140.s10|21-36|Coadministration|brand
DDI-DrugBank.d140.s10|41-52|atorvastatin|drug
DDI-DrugBank.d140.s10|90-92|AUC|brand
DDI-DrugBank.d140.s10|94-99|values|group
DDI-DrugBank.d140.s11|6-14|increases|group
DDI-DrugBank.d140.s11|93-104|atorvastatin|drug
DDI-DrugBank.d140.s12|10-21|Atorvastatin|drug
DDI-DrugBank.d140.s12|101-108|patients|group
DDI-DrugBank.d140.s13|10-17|Function|brand
DDI-DrugBank.d140.s13|19-25|HMG-CoA|brand
DDI-DrugBank.d140.s13|37-46|inhibitors|group
DDI-DrugBank.d140.s13|63-73|cholesterol|drug
DDI-DrugBank.d140.s13|75-83|synthesis|group
DDI-DrugBank.d140.s14|9-15|studies|group
DDI-DrugBank.d140.s14|33-44|atorvastatin|drug
DDI-DrugBank.d140.s15|4-10|effects|group
DDI-DrugBank.d140.s15|15-21|HMG-CoA|brand
DDI-DrugBank.d140.s15|33-42|inhibitors|group
DDI-DrugBank.d140.s15|96-102|numbers|group
DDI-DrugBank.d140.s15|107-114|patients|group
DDI-DrugBank.d140.s16|4-10|effects|group
DDI-DrugBank.d140.s16|46-49|axis|group
DDI-DrugBank.d140.s17|34-40|HMG-CoA|brand
DDI-DrugBank.d140.s17|97-101|drugs|group
DDI-DrugBank.d140.s17|125-130|levels|group
DDI-DrugBank.d140.s17|147-156|endogenous|group
DDI-DrugBank.d140.s17|166-173|hormones|group
DDI-DrugBank.d140.s17|184-195|ketoconazole|drug
DDI-DrugBank.d140.s17|198-211|spironolactone|drug_n
DDI-DrugBank.d140.s18|4-11|Toxicity|brand
DDI-DrugBank.d140.s18|13-17|Brain|brand
DDI-DrugBank.d140.s18|69-74|months|group
DDI-DrugBank.d140.s19|128-132|weeks|group
DDI-DrugBank.d140.s19|148-152|doses|group
DDI-DrugBank.d140.s20|68-72|times|group
DDI-DrugBank.d140.s20|123-127|hours|group
DDI-DrugBank.d140.s21|53-56|dogs|group
DDI-DrugBank.d140.s22|3-5|CNS|brand
DDI-DrugBank.d140.s22|7-13|lesions|group
DDI-DrugBank.d140.s22|78-82|years|group
DDI-DrugBank.d140.s22|87-91|doses|group
DDI-DrugBank.d140.s22|119-122|rats|group
DDI-DrugBank.d140.s22|127-131|doses|group
DDI-DrugBank.d140.s23|6-10|doses|group
DDI-DrugBank.d140.s23|25-29|times|group
DDI-DrugBank.d140.s23|51-55|times|group
DDI-DrugBank.d140.s23|73-75|AUC|brand
DDI-DrugBank.d140.s24|13-19|lesions|group
DDI-DrugBank.d140.s24|52-62|hemorrhages|group
DDI-DrugBank.d140.s24|122-127|spaces|group
DDI-DrugBank.d140.s24|152-155|dogs|group
DDI-DrugBank.d140.s24|176-182|members|group
DDI-DrugBank.d140.s24|192-196|class|group
DDI-DrugBank.d140.s25|34-38|class|group
DDI-DrugBank.d140.s25|118-123|fibers|group
DDI-DrugBank.d140.s25|147-150|dogs|group
DDI-DrugBank.d140.s25|216-221|levels|group
DDI-DrugBank.d140.s25|232-236|times|group
DDI-DrugBank.d140.s25|273-278|humans|group
DDI-MedLine.d53.s0|13-21|apoptosis|group
DDI-MedLine.d53.s0|40-44|cells|group
DDI-MedLine.d53.s0|61-69|vitamin D|group
DDI-MedLine.d53.s0|75-87|antiestrogens|group
DDI-MedLine.d53.s1|30-31|D3|brand
DDI-MedLine.d53.s1|73-81|vitamin D|group
DDI-MedLine.d53.s2|19-23|MCF-7|brand
DDI-MedLine.d53.s2|25-29|cells|group
DDI-MedLine.d53.s3|7-17|experiments|group
DDI-MedLine.d53.s3|50-61|interactions|group
DDI-MedLine.d53.s3|91-102|antiestrogen|group
DDI-MedLine.d53.s3|141-147|induces|group
DDI-MedLine.d53.s3|149-157|apoptosis|group
DDI-MedLine.d53.s3|162-166|MCF-7|brand
DDI-MedLine.d53.s3|168-172|cells|group
DDI-MedLine.d53.s4|22-24|TAM|brand
DDI-MedLine.d53.s4|40-50|potentiates|group
DDI-MedLine.d53.s5|40-42|TAM|brand
DDI-MedLine.d53.s5|44-51|enhances|group
DDI-MedLine.d53.s5|67-75|apoptosis|group
DDI-MedLine.d53.s5|106-112|markers|group
DDI-MedLine.d53.s6|31-35|MCF-7|brand
DDI-MedLine.d53.s6|37-41|cells|group
DDI-MedLine.d53.s6|68-78|(MCF-7D3Res|group
DDI-MedLine.d53.s7|6-10|cells|group
DDI-MedLine.d53.s7|12-18|express|group
DDI-MedLine.d53.s7|24-32|vitamin D|group
DDI-MedLine.d53.s7|64-68|times|group
DDI-MedLine.d53.s7|97-101|MCF-7|brand
DDI-MedLine.d53.s7|103-107|cells|group
DDI-MedLine.d53.s8|41-45|MCF-7|brand
DDI-MedLine.d53.s8|47-51|cells|group
DDI-MedLine.d53.s8|58-60|TAM|brand
DDI-MedLine.d53.s8|62-68|induces|group
DDI-MedLine.d53.s8|70-78|apoptosis|group
DDI-MedLine.d53.s9|26-34|apoptosis|group
DDI-MedLine.d53.s9|54-58|MCF-7|brand
DDI-MedLine.d53.s9|60-64|cells|group
DDI-DrugBank.d211.s0|46-50|drugs|group
DDI-DrugBank.d211.s1|13-21|Increased|brand
DDI-DrugBank.d211.s1|79-86|patients|group
DDI-DrugBank.d211.s2|15-25|Antibiotics|group
DDI-DrugBank.d211.s2|28-42|Chloramphenicol|brand
DDI-DrugBank.d211.s2|45-57|erythromycins|drug
DDI-DrugBank.d211.s2|60-71|sulfonamides|group
DDI-DrugBank.d211.s2|77-89|tetracyclines|group
DDI-DrugBank.d211.s2|137-147|penicillins|group
DDI-DrugBank.d211.s4|5-18|Contraceptives|group
DDI-DrugBank.d211.s4|21-23|May|brand
DDI-DrugBank.d211.s4|28-31|less|group
DDI-DrugBank.d211.s5|12-14|May|brand
DDI-DrugBank.d211.s5|92-97|levels|group
DDI-DrugBank.d211.s6|16-19|Test|brand
DDI-DrugBank.d211.s6|21-31|Interaction|brand
DDI-DrugBank.d211.s6|139-145|sulfate|drug
DDI-DrugBank.d211.s6|147-151|tests|group
DDI-DrugBank.d211.s6|153-162|(Benedicts|group
DDI-DrugBank.d211.s6|174-181|Fehlings|group
DDI-DrugBank.d211.s6|196-204|Clinitest|brand
DDI-DrugBank.d211.s6|206-212|tablets|group
DDI-DrugBank.d211.s6|241-245|tests|group
DDI-DrugBank.d211.s6|255-263|Clinistix|brand
DDI-DrugBank.d211.s6|269-275|Glucose|brand
DDI-DrugBank.d211.s6|277-285|Enzymatic|brand
DDI-DrugBank.d211.s6|287-290|Test|brand
DDI-DrugBank.d211.s6|292-296|Strip|brand
DDI-DrugBank.d211.s6|298-300|USP|brand
DDI-MedLine.d36.s0|49-62|antidepressant|group
DDI-MedLine.d36.s1|15-20|status|group
DDI-MedLine.d36.s1|39-46|presents|group
DDI-MedLine.d36.s1|90-96|depends|group
DDI-MedLine.d36.s1|136-142|studies|group
DDI-MedLine.d36.s1|169-177|prognosis|group
DDI-MedLine.d36.s2|49-61|consciousness|group
DDI-MedLine.d36.s2|122-135|antidepressant|group
DDI-MedLine.d36.s2|152-161|clinicians|group
DDI-MedLine.d36.s2|243-257|antidepressants|group
DDI-DrugBank.d398.s0|42-44|CNS|brand
DDI-DrugBank.d398.s0|57-63|effects|group
DDI-DrugBank.d398.s0|99-112|antihistamines|group
DDI-DrugBank.d398.s0|115-127|psychotropics|group
DDI-DrugBank.d398.s0|138-142|drugs|group
DDI-DrugBank.d398.s0|157-159|CNS|brand
DDI-DrugBank.d398.s1|0-6|Serious|group
DDI-DrugBank.d398.s1|89-98|inhibitors|group
DDI-DrugBank.d398.s1|100-105|(MAOIs|group
DDI-DrugBank.d398.s2|64-66|CNS|brand
DDI-DrugBank.d398.s2|79-85|effects|group
DDI-DrugBank.d398.s2|121-134|antihistamines|group
DDI-DrugBank.d398.s2|137-149|psychotropics|group
DDI-DrugBank.d398.s2|160-164|drugs|group
DDI-DrugBank.d398.s2|179-181|CNS|brand
DDI-MedLine.d88.s0|4-10|effects|group
DDI-MedLine.d88.s0|49-55|cocaine|drug
DDI-MedLine.d88.s0|60-68|bar-press|group
DDI-MedLine.d88.s0|105-111|nervous|group
DDI-MedLine.d88.s0|113-116|dogs|group
DDI-MedLine.d88.s1|0-6|Studies|group
DDI-MedLine.d88.s1|15-21|strains|group
DDI-MedLine.d88.s1|34-37|dogs|group
DDI-MedLine.d88.s1|116-126|facilitates|group
DDI-MedLine.d88.s2|0-7|subjects|group
DDI-MedLine.d88.s3|59-66|barpress|group
DDI-MedLine.d88.s3|95-98|dogs|group
DDI-MedLine.d88.s4|41-47|cocaine|drug
DDI-MedLine.d88.s4|65-73|compounds|group
DDI-MedLine.d88.s4|126-133|disrupts|group
DDI-MedLine.d88.s4|178-184|nervous|group
DDI-MedLine.d88.s4|186-193|E-strain|brand
DDI-MedLine.d88.s4|195-202|subjects|group
DDI-MedLine.d88.s4|244-251|A-strain|brand
DDI-MedLine.d88.s4|253-260|subjects|group
DDI-MedLine.d88.s5|31-34|days|group
DDI-MedLine.d88.s5|113-122|re-results|group
DDI-MedLine.d88.s5|143-146|loss|group
DDI-MedLine.d88.s5|151-159|bar-press|group
DDI-MedLine.d88.s5|177-184|E-strain|brand
DDI-MedLine.d88.s5|186-193|subjects|group
DDI-MedLine.d88.s5|204-210|results|group
DDI-MedLine.d88.s5|286-293|A-strain|brand
DDI-MedLine.d88.s5|295-302|subjects|group
DDI-DrugBank.d73.s0|24-28|drugs|group
DDI-DrugBank.d73.s0|90-102|beta-blocking|group
DDI-DrugBank.d73.s0|104-109|agents|group
DDI-DrugBank.d73.s1|0-7|Patients|group
DDI-DrugBank.d73.s1|22-29|TENORMIN|brand
DDI-DrugBank.d73.s1|31-34|plus|group
DDI-DrugBank.d73.s2|16-23|blockers|group
DDI-DrugBank.d73.s2|74-81|TENORMIN|brand
DDI-DrugBank.d73.s3|0-3|Beta|group
DDI-DrugBank.d73.s3|5-12|blockers|group
DDI-DrugBank.d73.s4|11-15|drugs|group
DDI-DrugBank.d73.s4|41-44|beta|group
DDI-DrugBank.d73.s4|82-85|days|group
DDI-DrugBank.d73.s5|26-37|beta-blocker|group
DDI-DrugBank.d73.s5|68-71|beta|group
DDI-DrugBank.d73.s5|73-80|blockers|group
DDI-DrugBank.d73.s5|112-115|days|group
DDI-DrugBank.d73.s6|53-57|drugs|group
DDI-DrugBank.d73.s6|107-113|effects|group
DDI-DrugBank.d73.s6|118-121|beta|group
DDI-DrugBank.d73.s6|123-130|blockers|group
DDI-DrugBank.d73.s7|35-42|atenolol|drug
DDI-DrugBank.d73.s8|18-24|studies|group
DDI-DrugBank.d73.s8|31-37|TIMI-II|brand
DDI-DrugBank.d73.s8|40-45|ISIS-2|brand
DDI-DrugBank.d73.s8|118-121|beta|group
DDI-DrugBank.d73.s8|123-130|blockers|group
DDI-DrugBank.d73.s9|13-16|beta|group
DDI-DrugBank.d73.s9|18-25|blockers|group
DDI-DrugBank.d73.s9|28-35|patients|group
DDI-DrugBank.d73.s9|93-101|allergens|group
DDI-DrugBank.d73.s10|5-12|patients|group
DDI-DrugBank.d73.s10|47-51|doses|group
DDI-MedLine.d15.s0|179-189|experiments|group
DDI-MedLine.d15.s0|205-208|rats|group
DDI-MedLine.d15.s0|260-263|days|group
DDI-MedLine.d15.s0|409-413|sites|group
DDI-MedLine.d15.s0|446-455|structures|group
DDI-MedLine.d15.s0|458-464|whereas|group
DDI-MedLine.d15.s0|517-521|sites|group
DDI-MedLine.d15.s0|592-601|structures|group
DDI-MedLine.d15.s1|34-45|neuroleptics|group
DDI-MedLine.d15.s2|91-95|sites|group
DDI-MedLine.d15.s2|131-150|serotonin2-receptors|group
DDI-MedLine.d15.s2|152-160|underlies|group
DDI-MedLine.d15.s2|166-178|antipsychotic|group
DDI-MedLine.d15.s2|190-201|neuroleptics|group
DDI-MedLine.d15.s3|84-95|neuroleptics|group
DDI-DrugBank.d79.s0|53-64|simultaneous|group
DDI-DrugBank.d79.s0|96-103|remedies|group
DDI-DrugBank.d79.s0|106-109|iron|drug_n
DDI-DrugBank.d79.s0|119-129|supplements|group
DDI-DrugBank.d79.s1|5-18|contraceptives|group
DDI-DrugBank.d79.s1|27-30|less|group
DDI-DrugBank.d71.s0|0-9|Lamivudine|drug
DDI-DrugBank.d71.s0|14-26|predominantly|drug
DDI-DrugBank.d71.s1|19-30|interactions|group
DDI-DrugBank.d71.s1|43-47|drugs|group
DDI-DrugBank.d71.s3|48-57|lamivudine|drug
DDI-DrugBank.d71.s3|59-74|pharmacokinetics|group
DDI-DrugBank.d71.s3|86-90|doses|group
DDI-DrugBank.d71.s3|95-101|TMP/SMX|brand
DDI-DrugBank.d71.s3|131-142|Pneumocystis|group
DDI-DrugBank.d71.s4|32-43|interactions|group
DDI-DrugBank.d71.s4|56-60|drugs|group
DDI-DrugBank.d71.s4|88-97|mechanisms|group
DDI-DrugBank.d71.s4|118-127|lamivudine|drug
DDI-DrugBank.d71.s5|0-9|Lamivudine|drug
DDI-DrugBank.d71.s6|18-27|lamivudine|drug
DDI-MedLine.d127.s0|14-19|levels|group
DDI-MedLine.d127.s0|44-50|antigen|group
DDI-MedLine.d127.s0|53-62|Validation|brand
DDI-MedLine.d127.s0|78-89|observations|group
DDI-MedLine.d127.s0|102-109|patients|group
DDI-MedLine.d127.s2|0-13|Determinations|group
DDI-MedLine.d127.s2|32-37|levels|group
DDI-MedLine.d127.s2|72-75|kits|group
DDI-MedLine.d127.s2|99-105|antigen|group
DDI-MedLine.d127.s2|154-160|results|group
DDI-MedLine.d127.s2|190-196|antigen|group
DDI-MedLine.d127.s4|62-67|levels|group
DDI-MedLine.d127.s4|115-119|hours|group
DDI-MedLine.d127.s6|20-27|thiazide|drug
DDI-MedLine.d127.s6|29-37|diuretics|group
DDI-MedLine.d127.s8|33-43|alterations|group
DDI-MedLine.d127.s8|54-59|levels|group
DDI-MedLine.d127.s8|154-160|effects|group
DDI-MedLine.d127.s10|62-69|patients|group
DDI-DrugBank.d496.s0|30-36|PROCRIT|brand
DDI-DrugBank.d496.s0|49-53|drugs|group
DDI-DrugBank.d496.s0|94-99|trials|group
DDI-DrugBank.d1.s0|5-16|interactions|group
DDI-DrugBank.d1.s0|26-33|NEUPOGEN|brand
DDI-DrugBank.d1.s0|46-50|drugs|group
DDI-DrugBank.d1.s1|0-4|Drugs|group
DDI-DrugBank.d1.s1|42-52|neutrophils|group
DDI-DrugBank.d56.s0|59-65|effects|group
DDI-MedLine.d4.s0|60-72|mono-oxidases|group
DDI-MedLine.d4.s0|104-110|effects|group
DDI-MedLine.d4.s0|194-203|activities|group
DDI-MedLine.d4.s1|120-125|Wistar|brand
DDI-MedLine.d4.s1|127-130|rats|group
DDI-MedLine.d4.s1|153-163|experiments|group
DDI-MedLine.d4.s3|4-11|findings|group
DDI-MedLine.d4.s3|47-53|effects|group
DDI-MedLine.d4.s3|69-78|activities|group
DDI-DrugBank.d404.s0|0-11|Interactions|group
DDI-DrugBank.d404.s0|17-25|vitamin D|group
DDI-DrugBank.d404.s0|27-35|analogues|group
DDI-DrugBank.d404.s0|46-47|D2|brand
DDI-DrugBank.d404.s0|50-59|Vitamin D3|group
DDI-DrugBank.d404.s0|62-71|Calcitriol|brand
DDI-DrugBank.d404.s0|78-86|Calcidiol|brand
DDI-DrugBank.d404.s0|90-103|Cholestyramine|brand
DDI-DrugBank.d404.s0|106-119|Cholestyramine|brand
DDI-DrugBank.d404.s0|186-193|vitamins|group
DDI-DrugBank.d404.s1|54-63|vitamin D.|group
DDI-DrugBank.d404.s2|0-22|Phenytoin/Phenobarbital|drug
DDI-DrugBank.d404.s2|62-74|phenobarbital|drug
DDI-DrugBank.d404.s2|99-112|concentrations|group
DDI-DrugBank.d404.s2|117-125|vitamin D|group
DDI-DrugBank.d404.s2|143-152|endogenous|group
DDI-DrugBank.d404.s2|161-166|levels|group
DDI-DrugBank.d404.s3|71-75|doses|group
DDI-DrugBank.d404.s3|80-88|Rocaltrol|brand
DDI-DrugBank.d404.s3|116-120|drugs|group
DDI-DrugBank.d404.s4|0-8|Thiazides|group
DDI-DrugBank.d404.s4|11-19|Thiazides|group
DDI-DrugBank.d404.s5|5-11|reports|group
DDI-DrugBank.d404.s5|63-71|thiazides|drug
DDI-DrugBank.d404.s5|78-86|vitamin D|group
DDI-DrugBank.d404.s5|88-93|causes|group
DDI-DrugBank.d404.s7|0-8|Digitalis|group
DDI-DrugBank.d404.s7|11-19|Vitamin D|group
DDI-DrugBank.d404.s7|60-67|patients|group
DDI-DrugBank.d404.s7|95-103|digitalis|group
DDI-DrugBank.d404.s7|131-138|patients|group
DDI-DrugBank.d404.s7|164-174|arrhythmias|group
DDI-DrugBank.d404.s8|0-11|Ketoconazole|drug
DDI-DrugBank.d404.s8|14-25|Ketoconazole|drug
DDI-DrugBank.d404.s8|68-74|enzymes|group
DDI-DrugBank.d404.s8|79-88|vitamin D.|group
DDI-DrugBank.d404.s9|0-9|Reductions|group
DDI-DrugBank.d404.s9|20-29|endogenous|group
DDI-DrugBank.d404.s9|31-39|vitamin D|group
DDI-DrugBank.d404.s9|41-54|concentrations|group
DDI-DrugBank.d404.s9|133-144|ketoconazole|drug
DDI-DrugBank.d404.s10|34-40|studies|group
DDI-DrugBank.d404.s10|45-56|ketoconazole|drug
DDI-DrugBank.d404.s10|63-71|vitamin D|group
DDI-DrugBank.d404.s11|0-14|Corticosteroids|group
DDI-DrugBank.d404.s11|57-62|exists|group
DDI-DrugBank.d404.s11|72-80|vitamin D|group
DDI-DrugBank.d404.s11|82-90|analogues|group
DDI-DrugBank.d404.s11|131-145|corticosteroids|group
DDI-DrugBank.d404.s12|18-23|Agents|group
DDI-DrugBank.d404.s12|26-30|Since|brand
DDI-DrugBank.d404.s12|32-40|vitamin D|group
DDI-DrugBank.d404.s12|102-108|kidneys|group
DDI-DrugBank.d404.s12|114-118|bones|group
DDI-DrugBank.d404.s12|153-158|agents|group
DDI-DrugBank.d404.s13|0-8|Vitamin D|group
DDI-DrugBank.d404.s13|46-54|vitamin D|group
DDI-DrugBank.d404.s13|56-64|analogues|group
DDI-DrugBank.d404.s13|123-129|effects|group
DDI-DrugBank.d404.s14|8-18|Supplements|group
DDI-DrugBank.d404.s14|21-32|Uncontrolled|brand
DDI-DrugBank.d404.s14|74-85|preparations|group
DDI-DrugBank.d404.s15|11-30|Magnesium-containing|brand
DDI-DrugBank.d404.s15|32-43|preparations|group
DDI-DrugBank.d404.s15|50-57|antacids|group
DDI-DrugBank.d404.s15|140-148|vitamin D|group
DDI-DrugBank.d404.s15|153-160|patients|group
DDI-DrugBank.d404.s15|179-186|dialysis|group
DDI-DrugBank.d82.s0|10-19|volunteers|group
DDI-DrugBank.d82.s0|147-152|levels|group
DDI-DrugBank.d82.s1|8-15|patients|group
DDI-DrugBank.d82.s1|34-40|INDOCIN|brand
DDI-DrugBank.d82.s2|26-32|INDOCIN|brand
DDI-DrugBank.d82.s3|21-30|volunteers|group
DDI-DrugBank.d82.s3|113-121|decreases|group
DDI-DrugBank.d82.s3|142-147|levels|group
DDI-DrugBank.d82.s4|23-29|INDOCIN|brand
DDI-DrugBank.d82.s4|42-47|NSAIDs|group
DDI-DrugBank.d82.s5|9-15|studies|group
DDI-DrugBank.d82.s5|33-39|INDOCIN|brand
DDI-DrugBank.d82.s5|96-109|anticoagulants|group
DDI-DrugBank.d82.s6|45-51|INDOCIN|brand
DDI-DrugBank.d82.s6|83-90|patients|group
DDI-DrugBank.d82.s6|95-107|anticoagulant|group
DDI-DrugBank.d82.s6|122-129|patients|group
DDI-DrugBank.d82.s6|154-164|alterations|group
DDI-DrugBank.d82.s7|60-67|patients|group
DDI-DrugBank.d82.s7|99-112|anticoagulants|group
DDI-DrugBank.d82.s7|118-124|INDOCIN|brand
DDI-DrugBank.d82.s8|33-39|INDOCIN|brand
DDI-DrugBank.d82.s8|45-58|anticoagulants|group
DDI-DrugBank.d82.s9|5-11|INDOCIN|brand
DDI-DrugBank.d82.s9|25-32|patients|group
DDI-DrugBank.d82.s9|67-72|levels|group
DDI-DrugBank.d82.s10|41-47|INDOCIN|brand
DDI-DrugBank.d82.s11|5-13|increases|group
DDI-DrugBank.d82.s11|30-36|INDOCIN|brand
DDI-DrugBank.d82.s11|91-100|increments|group
DDI-DrugBank.d82.s12|26-32|INDOCIN|brand
DDI-DrugBank.d82.s14|32-48|anti-inflammatory|group
DDI-DrugBank.d82.s14|50-54|drugs|group
DDI-DrugBank.d82.s14|185-193|synthesis|group
DDI-DrugBank.d82.s15|0-5|NSAIDs|group
DDI-DrugBank.d82.s15|38-45|patients|group
DDI-DrugBank.d82.s16|0-7|Capsules|group
DDI-DrugBank.d82.s16|9-15|INDOCIN|brand
DDI-DrugBank.d82.s16|145-152|patients|group
DDI-DrugBank.d82.s16|165-172|subjects|group
DDI-DrugBank.d82.s16|207-220|concentrations|group
DDI-DrugBank.d82.s17|63-71|synthesis|group
DDI-DrugBank.d82.s18|23-29|INDOCIN|brand
DDI-DrugBank.d82.s18|113-117|signs|group
DDI-DrugBank.d82.s19|6-14|circulars|group
DDI-DrugBank.d82.s19|28-39|preparations|group
DDI-DrugBank.d82.s22|16-22|INDOCIN|brand
DDI-DrugBank.d82.s22|74-79|levels|group
DDI-DrugBank.d82.s23|8-15|patients|group
DDI-DrugBank.d82.s23|40-46|INDOCIN|brand
DDI-DrugBank.d82.s23|90-105|antihypertensive|group
DDI-DrugBank.d82.s23|107-113|effects|group
DDI-DrugBank.d82.s23|124-140|potassium-sparing|drug
DDI-DrugBank.d82.s23|147-154|thiazide|drug
DDI-DrugBank.d82.s23|156-164|diuretics|group
DDI-DrugBank.d82.s24|16-22|INDOCIN|brand
DDI-DrugBank.d82.s24|28-34|INDOCIN|brand
DDI-DrugBank.d82.s25|15-23|diuretics|group
DDI-DrugBank.d82.s26|8-14|reduces|group
DDI-DrugBank.d82.s26|68-77|elevations|group
DDI-DrugBank.d82.s26|82-84|PRA|brand
DDI-DrugBank.d82.s26|97-106|furosemide|drug
DDI-DrugBank.d82.s27|6-10|facts|group
DDI-DrugBank.d82.s27|87-94|patients|group
DDI-DrugBank.d82.s28|83-89|INDOCIN|brand
DDI-DrugBank.d82.s28|157-166|volunteers|group
DDI-DrugBank.d82.s30|12-28|potassium-sparing|drug
DDI-DrugBank.d82.s30|30-38|diuretics|group
DDI-DrugBank.d82.s30|94-99|levels|group
DDI-DrugBank.d82.s31|14-20|effects|group
DDI-DrugBank.d82.s31|25-31|INDOCIN|brand
DDI-DrugBank.d82.s31|37-53|potassium-sparing|drug
DDI-DrugBank.d82.s31|55-63|diuretics|group
DDI-DrugBank.d82.s31|78-85|kinetics|group
DDI-DrugBank.d82.s31|138-143|agents|group
DDI-DrugBank.d82.s32|18-24|effects|group
DDI-DrugBank.d82.s32|37-45|diuretics|group
DDI-DrugBank.d82.s32|90-99|mechanisms|group
DDI-DrugBank.d82.s32|139-147|synthesis|group
DDI-DrugBank.d82.s32|152-158|INDOCIN|brand
DDI-DrugBank.d82.s33|16-31|antihypertensive|group
DDI-DrugBank.d82.s33|43-59|beta-adrenoceptor|group
DDI-DrugBank.d82.s33|70-75|agents|group
DDI-DrugBank.d82.s33|94-109|antiinflammatory|group
DDI-DrugBank.d82.s33|111-115|drugs|group
DDI-DrugBank.d82.s33|127-133|INDOCIN|brand
DDI-DrugBank.d82.s34|37-42|agents|group
DDI-DrugBank.d82.s34|67-74|patients|group
DDI-DrugBank.d82.s35|23-38|antihypertensive|group
DDI-DrugBank.d82.s35|40-46|effects|group
DDI-DrugBank.d82.s35|51-59|captopril|drug
DDI-DrugBank.d82.s35|65-72|losartan|drug
DDI-DrugBank.d82.s36|15-21|results|group
DDI-DrugBank.d82.s36|30-42|dexamethasone|drug
DDI-DrugBank.d82.s36|70-77|patients|group
DDI-DrugBank.d82.s36|98-104|INDOCIN|brand
DDI-DrugBank.d82.s37|0-3|Thus|group
DDI-DrugBank.d82.s37|6-12|results|group
DDI-DrugBank.d82.s37|21-23|DST|brand
DDI-DrugBank.d82.s37|69-76|patients|group
DDI-DrugBank.d85.s0|11-16|NSAIDs|group
DDI-DrugBank.d85.s0|21-28|patients|group
DDI-DrugBank.d85.s0|48-50|ACE|brand
DDI-DrugBank.d85.s0|52-61|inhibitors|group
DDI-DrugBank.d85.s0|92-97|states|group
DDI-DrugBank.d85.s1|9-15|studies|group
DDI-DrugBank.d85.s1|118-122|sites|group
DDI-DrugBank.d85.s1|130-134|drugs|group
DDI-DrugBank.d85.s3|22-28|studies|group
DDI-DrugBank.d85.s3|80-86|affects|group
DDI-DrugBank.d85.s3|100-104|times|group
DDI-DrugBank.d85.s3|127-137|individuals|group
DDI-DrugBank.d85.s3|156-169|anticoagulants|group
DDI-DrugBank.d85.s4|19-29|nonetheless|group
DDI-DrugBank.d85.s4|38-49|interactions|group
DDI-DrugBank.d85.s4|90-95|agents|group
DDI-DrugBank.d85.s4|105-109|class|group
DDI-DrugBank.d85.s5|11-18|patients|group
DDI-DrugBank.d85.s5|107-111|signs|group
DDI-DrugBank.d85.s5|134-138|drugs|group
DDI-DrugBank.d85.s6|117-121|sites|group
DDI-DrugBank.d85.s6|199-212|concentrations|group
DDI-DrugBank.d85.s6|230-235|levels|group
DDI-DrugBank.d85.s7|26-35|furosemide|drug
DDI-DrugBank.d85.s7|79-83|drugs|group
DDI-DrugBank.d85.s7|93-97|class|group
DDI-DrugBank.d85.s8|49-57|increases|group
DDI-DrugBank.d85.s8|77-90|concentrations|group
DDI-DrugBank.d85.s9|19-24|NSAIDs|group
DDI-DrugBank.d85.s9|41-56|antihypertensive|group
DDI-DrugBank.d85.s9|68-78|propranolol|drug
DDI-DrugBank.d85.s9|90-102|beta-blockers|group
DDI-DrugBank.d85.s10|30-38|increases|group
DDI-DrugBank.d85.s10|62-67|levels|group
DDI-DrugBank.d85.s10|73-79|extends|group
DDI-DrugBank.d85.s12|36-41|NSAIDs|group
DDI-DrugBank.d85.s13|16-19|Test|brand
DDI-DrugBank.d85.s13|21-32|Interactions|group
DDI-DrugBank.d85.s13|34-41|Naproxen|brand
DDI-DrugBank.d85.s14|49-53|times|group
DDI-DrugBank.d85.s15|63-68|values|group
DDI-DrugBank.d85.s15|87-94|steroids|group
DDI-DrugBank.d85.s15|150-160|metabolites|group
DDI-DrugBank.d85.s16|35-46|measurements|group
DDI-DrugBank.d85.s16|186-190|hours|group
DDI-DrugBank.d85.s16|216-220|tests|group
DDI-DrugBank.d85.s16|243-255|Porter-Silber|brand
DDI-DrugBank.d85.s17|41-46|assays|group
DDI-DrugBank.d85.s17|61-77|indoleacetic acid|drug
DDI-MedLine.d135.s0|0-11|Combinations|group
DDI-MedLine.d135.s0|45-51|effects|group
DDI-MedLine.d135.s0|105-108|rats|group
DDI-MedLine.d135.s1|14-17|(PCP|drug_n
DDI-MedLine.d135.s1|20-27|produces|group
DDI-MedLine.d135.s1|45-51|effects|group
DDI-MedLine.d135.s1|56-61|humans|group
DDI-MedLine.d135.s1|91-98|symptoms|group
DDI-MedLine.d135.s2|23-31|compounds|group
DDI-MedLine.d135.s2|37-49|antipsychotic|group
DDI-MedLine.d135.s2|73-83|researchers|group
DDI-MedLine.d135.s2|117-125|compounds|group
DDI-MedLine.d135.s2|133-143|PCP-induced|drug_n
DDI-MedLine.d135.s2|145-153|behaviors|group
DDI-MedLine.d135.s2|158-164|animals|group
DDI-MedLine.d135.s3|35-47|antipsychotic|group
DDI-MedLine.d135.s3|108-110|PCP|drug_n
DDI-MedLine.d135.s3|177-215|differential-reinforcement-of-low-rates|group
DDI-MedLine.d135.s3|223-232|procedures|group
DDI-MedLine.d135.s4|0-2|PCP|drug_n
DDI-MedLine.d135.s4|25-31|effects|group
DDI-MedLine.d135.s4|87-89|PCP|drug_n
DDI-MedLine.d135.s4|137-145|responses|group
DDI-MedLine.d135.s4|162-162|s|group
DDI-MedLine.d135.s4|179-183|times|group
DDI-MedLine.d135.s4|224-228|rates|group
DDI-MedLine.d135.s4|237-239|DRL|brand
DDI-MedLine.d135.s5|59-65|effects|group
DDI-MedLine.d135.s5|70-72|PCP|drug_n
DDI-MedLine.d135.s5|117-121|doses|group
DDI-MedLine.d135.s5|153-159|effects|group
DDI-MedLine.d135.s6|6-12|results|group
DDI-MedLine.d135.s6|72-80|behaviors|group
DDI-MedLine.d135.s6|111-113|PCP|drug_n
DDI-MedLine.d135.s7|55-57|PCP|drug_n
DDI-MedLine.d135.s7|71-80|procedures|group
DDI-MedLine.d135.s7|85-91|animals|group
DDI-MedLine.d135.s7|107-119|antipsychotic|group
DDI-MedLine.d135.s8|61-74|antipsychotics|group
DDI-MedLine.d135.s8|84-90|studies|group
DDI-MedLine.d135.s8|99-103|focus|group
DDI-MedLine.d135.s8|140-146|effects|group
DDI-MedLine.d135.s8|157-161|drugs|group
DDI-MedLine.d135.s8|183-185|PCP|drug_n
DDI-DrugBank.d158.s0|19-24|agents|group
DDI-DrugBank.d158.s0|32-37|agents|group
DDI-DrugBank.d158.s0|59-69|sodium acid|drug
DDI-DrugBank.d158.s0|130-136|species|group
DDI-DrugBank.d158.s1|5-10|groups|group
DDI-DrugBank.d158.s1|15-20|agents|group
DDI-DrugBank.d158.s1|34-39|levels|group
DDI-DrugBank.d158.s1|57-68|amphetamines|group
DDI-DrugBank.d158.s2|11-18|blockers|group
DDI-DrugBank.d158.s2|20-29|Adrenergic|brand
DDI-DrugBank.d158.s2|31-38|blockers|group
DDI-DrugBank.d158.s2|57-68|amphetamines|group
DDI-DrugBank.d158.s3|0-14|Antidepressants|group
DDI-DrugBank.d158.s3|27-38|Amphetamines|group
DDI-DrugBank.d158.s3|78-92|antidepressants|group
DDI-DrugBank.d158.s3|113-118|agents|group
DDI-DrugBank.d158.s4|19-29|desipramine|drug
DDI-DrugBank.d158.s4|34-46|protriptyline|drug
DDI-DrugBank.d158.s4|67-76|tricyclics|group
DDI-DrugBank.d158.s4|107-115|increases|group
DDI-DrugBank.d158.s5|15-21|effects|group
DDI-DrugBank.d158.s6|4-13|inhibitors|group
DDI-DrugBank.d158.s6|15-18|MAOI|brand
DDI-DrugBank.d158.s6|20-34|antidepressants|group
DDI-DrugBank.d158.s7|13-23|potentiates|group
DDI-DrugBank.d158.s7|25-36|amphetamines|group
DDI-DrugBank.d158.s7|106-115|monoamines|group
DDI-DrugBank.d158.s7|139-145|endings|group
DDI-DrugBank.d158.s8|15-23|headaches|group
DDI-DrugBank.d158.s8|35-39|signs|group
DDI-DrugBank.d158.s8|57-62|crisis|group
DDI-DrugBank.d158.s9|32-38|effects|group
DDI-DrugBank.d158.s9|78-86|sometimes|group
DDI-DrugBank.d158.s9|99-105|results|group
DDI-DrugBank.d158.s10|0-13|Antihistamines|group
DDI-DrugBank.d158.s10|16-27|Amphetamines|group
DDI-DrugBank.d158.s10|67-80|antihistamines|group
DDI-DrugBank.d158.s11|0-16|Antihypertensives|group
DDI-DrugBank.d158.s11|19-30|Amphetamines|group
DDI-DrugBank.d158.s11|63-69|effects|group
DDI-DrugBank.d158.s11|74-90|antihypertensives|group
DDI-DrugBank.d158.s12|16-29|Chlorpromazine|brand
DDI-DrugBank.d158.s12|31-36|blocks|group
DDI-DrugBank.d158.s12|66-74|receptors|group
DDI-DrugBank.d158.s12|77-80|thus|group
DDI-DrugBank.d158.s12|115-121|effects|group
DDI-DrugBank.d158.s12|126-137|amphetamines|group
DDI-DrugBank.d158.s13|14-25|Amphetamines|group
DDI-DrugBank.d158.s14|13-23|Haloperidol|brand
DDI-DrugBank.d158.s14|25-30|blocks|group
DDI-DrugBank.d158.s14|41-49|receptors|group
DDI-DrugBank.d158.s14|52-55|thus|group
DDI-DrugBank.d158.s14|90-96|effects|group
DDI-DrugBank.d158.s14|101-112|amphetamines|group
DDI-DrugBank.d158.s15|49-55|effects|group
DDI-DrugBank.d158.s15|60-71|amphetamines|group
DDI-DrugBank.d158.s16|12-23|Amphetamines|group
DDI-DrugBank.d158.s17|20-26|Urinary|brand
DDI-DrugBank.d158.s17|41-52|amphetamines|group
DDI-DrugBank.d158.s17|106-111|agents|group
DDI-DrugBank.d158.s18|16-27|Amphetamines|group
DDI-DrugBank.d158.s19|0-12|Phenobarbital|drug
DDI-DrugBank.d158.s19|15-26|Amphetamines|group
DDI-DrugBank.d158.s19|63-75|phenobarbital|drug
DDI-DrugBank.d158.s20|21-33|phenobarbital|drug
DDI-DrugBank.d158.s20|61-74|anticonvulsant|group
DDI-DrugBank.d158.s21|11-22|Amphetamines|group
DDI-DrugBank.d158.s22|57-70|anticonvulsant|group
DDI-DrugBank.d158.s23|17-21|cases|group
DDI-DrugBank.d158.s23|63-65|CNS|brand
DDI-DrugBank.d158.s23|104-114|convulsions|group
DDI-DrugBank.d158.s24|9-17|alkaloids|group
DDI-DrugBank.d158.s24|20-31|Amphetamines|group
DDI-DrugBank.d158.s24|76-84|alkaloids|group
DDI-DrugBank.d158.s25|16-19|Test|brand
DDI-DrugBank.d158.s25|21-32|Interactions|group
DDI-DrugBank.d158.s25|35-46|Amphetamines|group
DDI-DrugBank.d158.s25|107-112|levels|group
DDI-DrugBank.d158.s27|0-11|Amphetamines|group
DDI-DrugBank.d158.s27|48-61|determinations|group
DDI-DrugBank.d4.s0|27-41|bronchodilators|group
DDI-DrugBank.d4.s0|50-61|theophylline|drug
DDI-DrugBank.d4.s0|102-116|bronchodilators|group
DDI-DrugBank.d4.s1|41-46|agents|group
DDI-DrugBank.d4.s2|29-38|dyphylline|drug
DDI-DrugBank.d4.s2|62-69|competes|group
DDI-DrugBank.d4.s2|145-154|dyphylline|drug
DDI-DrugBank.d357.s0|5-15|Antagonists|group
DDI-DrugBank.d357.s0|18-22|Based|brand
DDI-DrugBank.d357.s0|27-33|reports|group
DDI-DrugBank.d357.s0|63-66|loss|group
DDI-DrugBank.d357.s0|71-83|consciousness|group
DDI-DrugBank.d357.s0|124-134|ondansetron|drug
DDI-DrugBank.d357.s0|177-181|drugs|group
DDI-DrugBank.d357.s0|206-210|class|group
DDI-DrugBank.d357.s0|237-247|ondansetron|drug
DDI-DrugBank.d357.s0|250-260|granisetron|drug
DDI-DrugBank.d357.s0|263-272|dolasetron|drug
DDI-DrugBank.d357.s0|275-286|palonosetron|drug
DDI-DrugBank.d357.s0|293-301|alosetron|drug
DDI-DrugBank.d357.s1|0-15|Antihypertensive|group
DDI-DrugBank.d357.s1|17-27|Medications|group
DDI-DrugBank.d357.s1|33-44|Vasodilators|group
DDI-DrugBank.d357.s1|69-74|events|group
DDI-DrugBank.d357.s1|110-117|patients|group
DDI-DrugBank.d357.s1|141-156|antihypertensive|group
DDI-DrugBank.d357.s1|158-168|medications|group
DDI-DrugBank.d357.s1|173-184|vasodilators|group
DDI-DrugBank.d357.s1|207-214|patients|group
DDI-DrugBank.d357.s1|248-252|drugs|group
DDI-DrugBank.d357.s1|281-282|vs|group
DDI-DrugBank.d357.s1|313-314|vs|group
DDI-DrugBank.d357.s1|320-326|serious|group
DDI-DrugBank.d357.s1|341-342|vs|group
DDI-DrugBank.d357.s1|348-354|serious|group
DDI-DrugBank.d357.s1|356-360|falls|group
DDI-DrugBank.d357.s1|365-366|vs|group
DDI-DrugBank.d357.s1|391-398|injuries|group
DDI-DrugBank.d357.s1|403-404|vs|group
DDI-DrugBank.d357.s2|39-44|events|group
DDI-DrugBank.d357.s3|9-19|Antagonists|group
DDI-DrugBank.d357.s3|22-26|Since|brand
DDI-DrugBank.d357.s3|92-102|antagonists|group
DDI-DrugBank.d357.s3|117-128|neuroleptics|group
DDI-DrugBank.d357.s3|130-144|(phenothiazines|group
DDI-DrugBank.d357.s3|147-160|butyrophenones|group
DDI-DrugBank.d357.s3|163-175|thioxanthenes|group
DDI-DrugBank.d357.s3|214-226|effectiveness|group
DDI-DrugBank.d357.s3|231-236|APOKYN|brand
DDI-DrugBank.d357.s4|0-7|Patients|group
DDI-DrugBank.d357.s4|30-38|disorders|group
DDI-DrugBank.d357.s4|54-65|neuroleptics|group
DDI-DrugBank.d357.s4|100-107|agonists|group
DDI-DrugBank.d357.s4|131-138|benefits|group
DDI-DrugBank.d357.s4|153-157|risks|group
DDI-DrugBank.d357.s5|0-4|Drugs|group
DDI-DrugBank.d357.s5|6-15|Prolonging|brand
DDI-DrugBank.d357.s5|21-26|QT/QTc|brand
DDI-DrugBank.d357.s5|28-35|Interval|brand
DDI-DrugBank.d357.s5|37-43|Caution|brand
DDI-DrugBank.d357.s5|113-117|drugs|group
DDI-DrugBank.d357.s5|136-141|QT/QTc|brand
DDI-DrugBank.d357.s6|16-19|Test|brand
DDI-DrugBank.d357.s6|21-32|Interactions|group
DDI-DrugBank.d357.s6|53-64|interactions|group
DDI-DrugBank.d357.s6|74-79|APOKYN|brand
DDI-DrugBank.d357.s6|96-100|tests|group
DDI-DrugBank.d564.s0|39-47|solutions|group
DDI-DrugBank.d564.s0|93-100|patients|group
DDI-DrugBank.d564.s0|130-139|inhibitors|group
DDI-DrugBank.d564.s0|154-168|antidepressants|group
DDI-DrugBank.d564.s1|0-13|Phenothiazines|group
DDI-DrugBank.d564.s1|19-32|butyrophenones|group
DDI-DrugBank.d564.s2|24-29|agents|group
DDI-DrugBank.d564.s3|3-12|situations|group
DDI-DrugBank.d564.s4|41-45|drugs|group
DDI-DrugBank.d564.s4|102-107|blocks|group
DDI-DrugBank.d564.s4|134-138|drugs|group
DDI-DrugBank.d564.s4|201-209|accidents|group
DDI-DrugBank.d147.s0|10-20|assessments|group
DDI-DrugBank.d147.s0|35-46|interactions|group
DDI-DrugBank.d147.s0|56-61|Vidaza|brand
DDI-DrugBank.d147.s0|73-78|agents|group
DDI-DrugBank.d434.s0|91-96|trials|group
DDI-DrugBank.d434.s0|102-108|studies|group
DDI-DrugBank.d434.s0|138-143|adults|group
DDI-DrugBank.d434.s1|7-17|Conjunction|brand
DDI-DrugBank.d434.s1|30-42|Antiepileptic|group
DDI-DrugBank.d434.s1|44-48|Drugs|group
DDI-DrugBank.d434.s1|67-74|Felbatol|brand
DDI-DrugBank.d434.s1|80-92|antiepileptic|group
DDI-DrugBank.d434.s1|94-98|drugs|group
DDI-DrugBank.d434.s1|100-104|(AEDs|group
DDI-DrugBank.d434.s1|107-113|affects|group
DDI-DrugBank.d434.s1|139-152|concentrations|group
DDI-DrugBank.d434.s1|157-160|AEDs|group
DDI-DrugBank.d434.s2|24-35|interactions|group
DDI-DrugBank.d434.s2|75-77|AED|brand
DDI-DrugBank.d434.s2|79-81|AED|brand
DDI-DrugBank.d434.s2|83-90|Felbatol|brand
DDI-DrugBank.d434.s3|15-27|Concentration|brand
DDI-DrugBank.d434.s3|29-41|Concentration|brand
DDI-DrugBank.d434.s8|0-12|Phenobarbital|drug
DDI-DrugBank.d434.s11|9-15|Effects|group
DDI-DrugBank.d434.s11|20-27|Felbatol|brand
DDI-DrugBank.d434.s11|39-51|Antiepileptic|group
DDI-DrugBank.d434.s11|53-57|Drugs|group
DDI-DrugBank.d434.s11|59-67|Phenytoin|brand
DDI-DrugBank.d434.s11|70-77|Felbatol|brand
DDI-DrugBank.d434.s11|80-85|causes|group
DDI-DrugBank.d434.s11|132-145|concentrations|group
DDI-DrugBank.d434.s12|24-31|subjects|group
DDI-DrugBank.d434.s13|17-20|Cmin|brand
DDI-DrugBank.d434.s14|61-68|subjects|group
DDI-DrugBank.d434.s14|107-110|Cmin|brand
DDI-DrugBank.d434.s15|31-36|levels|group
DDI-DrugBank.d434.s15|53-63|experiences|group
DDI-DrugBank.d434.s15|197-204|subjects|group
DDI-DrugBank.d434.s16|91-98|Felbatol|brand
DDI-DrugBank.d434.s16|131-136|levels|group
DDI-DrugBank.d434.s16|167-174|Felbatol|brand
DDI-DrugBank.d434.s17|15-22|Felbatol|brand
DDI-DrugBank.d434.s17|25-30|causes|group
DDI-DrugBank.d434.s17|84-97|concentrations|group
DDI-DrugBank.d434.s18|26-33|subjects|group
DDI-DrugBank.d434.s19|31-34|Cmin|brand
DDI-DrugBank.d434.s19|119-123|doses|group
DDI-DrugBank.d434.s20|35-38|Cmin|brand
DDI-DrugBank.d434.s20|40-53|concentrations|group
DDI-DrugBank.d434.s21|12-17|trials|group
DDI-DrugBank.d434.s21|28-34|changes|group
DDI-DrugBank.d434.s22|11-18|Felbatol|brand
DDI-DrugBank.d434.s22|21-26|causes|group
DDI-DrugBank.d434.s22|66-79|concentrations|group
DDI-DrugBank.d434.s23|8-15|subjects|group
DDI-DrugBank.d434.s24|17-20|Cmin|brand
DDI-DrugBank.d434.s25|81-84|Cmin|brand
DDI-DrugBank.d434.s26|14-19|values|group
DDI-DrugBank.d434.s26|40-43|Cmin|brand
DDI-DrugBank.d434.s26|45-58|concentrations|group
DDI-DrugBank.d434.s26|127-134|Felbatol|brand
DDI-DrugBank.d434.s27|4-9|ratios|group
DDI-DrugBank.d434.s27|18-21|AUCs|group
DDI-DrugBank.d434.s27|51-54|AUCs|group
DDI-DrugBank.d434.s27|163-170|Felbatol|brand
DDI-DrugBank.d434.s28|0-12|Phenobarbital|drug
DDI-DrugBank.d434.s28|15-30|Coadministration|brand
DDI-DrugBank.d434.s28|50-62|phenobarbital|drug
DDI-DrugBank.d434.s28|64-69|causes|group
DDI-DrugBank.d434.s28|86-98|phenobarbital|drug
DDI-DrugBank.d434.s28|107-120|concentrations|group
DDI-DrugBank.d434.s28|152-161|volunteers|group
DDI-DrugBank.d434.s28|173-185|phenobarbital|drug
DDI-DrugBank.d434.s28|219-231|phenobarbital|drug
DDI-DrugBank.d434.s29|17-20|Cmin|brand
DDI-DrugBank.d434.s30|0-6|Effects|group
DDI-DrugBank.d434.s30|17-29|Antiepileptic|group
DDI-DrugBank.d434.s30|31-35|Drugs|group
DDI-DrugBank.d434.s30|40-47|Felbatol|brand
DDI-DrugBank.d434.s30|50-58|Phenytoin|brand
DDI-DrugBank.d434.s30|61-69|Phenytoin|brand
DDI-DrugBank.d434.s30|71-76|causes|group
DDI-DrugBank.d434.s30|122-129|Felbatol|brand
DDI-DrugBank.d434.s30|202-207|causes|group
DDI-DrugBank.d434.s30|264-277|concentrations|group
DDI-DrugBank.d434.s30|282-289|Felbatol|brand
DDI-DrugBank.d434.s30|324-331|Felbatol|brand
DDI-DrugBank.d434.s31|15-27|Carbamazepine|brand
DDI-DrugBank.d434.s31|29-34|causes|group
DDI-DrugBank.d434.s31|84-91|Felbatol|brand
DDI-DrugBank.d434.s31|156-162|results|group
DDI-DrugBank.d434.s31|222-235|concentrations|group
DDI-DrugBank.d434.s31|240-247|Felbatol|brand
DDI-DrugBank.d434.s31|282-289|Felbatol|brand
DDI-DrugBank.d434.s32|11-19|Available|brand
DDI-DrugBank.d434.s32|103-110|Felbatol|brand
DDI-DrugBank.d434.s32|130-138|Therefore|brand
DDI-DrugBank.d434.s32|225-232|Felbatol|brand
DDI-DrugBank.d434.s32|254-267|concentrations|group
DDI-DrugBank.d434.s33|0-12|Phenobarbital|drug
DDI-DrugBank.d434.s33|18-24|appears|group
DDI-DrugBank.d434.s33|31-43|phenobarbital|drug
DDI-DrugBank.d434.s33|73-86|concentrations|group
DDI-DrugBank.d434.s34|30-43|concentrations|group
DDI-DrugBank.d434.s34|86-99|concentrations|group
DDI-DrugBank.d434.s34|131-138|subjects|group
DDI-DrugBank.d434.s35|0-6|Effects|group
DDI-DrugBank.d434.s35|11-18|Antacids|group
DDI-DrugBank.d434.s35|23-30|Felbatol|brand
DDI-DrugBank.d434.s35|88-95|Felbatol|brand
DDI-DrugBank.d434.s35|122-128|tablets|group
DDI-DrugBank.d434.s35|172-179|antacids|group
DDI-DrugBank.d434.s36|0-6|Effects|group
DDI-DrugBank.d434.s36|11-22|Erythromycin|drug
DDI-DrugBank.d434.s36|27-34|Felbatol|brand
DDI-DrugBank.d434.s36|61-72|erythromycin|drug
DDI-DrugBank.d434.s36|95-98|days|group
DDI-DrugBank.d434.s36|134-143|parameters|group
DDI-DrugBank.d434.s36|148-151|Cmax|brand
DDI-DrugBank.d434.s36|154-157|Cmin|brand
DDI-DrugBank.d434.s36|160-162|AUC|brand
DDI-DrugBank.d434.s36|165-169|CI/kg|brand
DDI-DrugBank.d434.s36|198-202|doses|group
DDI-DrugBank.d434.s36|251-258|subjects|group
DDI-DrugBank.d434.s37|0-6|Effects|group
DDI-DrugBank.d434.s37|11-18|Felbatol|brand
DDI-DrugBank.d434.s37|24-31|Low-Dose|brand
DDI-DrugBank.d434.s37|33-43|Combination|brand
DDI-DrugBank.d434.s37|45-48|Oral|brand
DDI-DrugBank.d434.s37|50-63|Contraceptives|group
DDI-DrugBank.d434.s37|112-121|volunteers|group
DDI-DrugBank.d434.s37|238-243|months|group
DDI-DrugBank.d434.s37|361-366|cycles|group
DDI-DrugBank.d434.s38|64-66|AUC|brand
DDI-DrugBank.d434.s38|144-153|parameters|group
DDI-DrugBank.d499.s0|19-30|interactions|group
DDI-DrugBank.d499.s0|50-59|ketoprofen|drug
DDI-DrugBank.d499.s0|61-65|doses|group
DDI-DrugBank.d499.s1|69-74|Orudis|group
DDI-DrugBank.d499.s1|76-80|doses|group
DDI-DrugBank.d499.s1|131-140|ketoprofen|drug
DDI-DrugBank.d499.s1|191-195|drugs|group
DDI-DrugBank.d499.s3|0-7|Antacids|group
DDI-DrugBank.d499.s3|10-20|Concomitant|brand
DDI-DrugBank.d499.s3|147-156|ketoprofen|drug
DDI-DrugBank.d499.s3|174-179|Orudis|group
DDI-DrugBank.d499.s5|9-18|Ketoprofen|drug
DDI-DrugBank.d499.s6|33-40|subjects|group
DDI-DrugBank.d499.s6|90-99|ketoprofen|drug
DDI-DrugBank.d499.s6|131-140|ketoprofen|drug
DDI-DrugBank.d499.s6|169-174|L/kg/h|brand
DDI-DrugBank.d499.s6|200-205|L/kg/h|brand
DDI-DrugBank.d499.s7|35-41|changes|group
DDI-DrugBank.d499.s8|41-50|ketoprofen|drug
DDI-DrugBank.d499.s10|10-28|Hydrochlorothiazide|drug
DDI-DrugBank.d499.s10|56-65|ketoprofen|drug
DDI-DrugBank.d499.s10|68-75|produces|group
DDI-DrugBank.d499.s10|145-163|hydrochlorothiazide|drug
DDI-DrugBank.d499.s11|0-7|Patients|group
DDI-DrugBank.d499.s11|16-24|diuretics|group
DDI-DrugBank.d499.s13|26-33|patients|group
DDI-DrugBank.d499.s13|71-80|ketoprofen|drug
DDI-DrugBank.d499.s13|127-136|ketoprofen|drug
DDI-DrugBank.d499.s13|162-167|levels|group
DDI-DrugBank.d499.s15|56-65|volunteers|group
DDI-DrugBank.d499.s15|68-77|ketoprofen|drug
DDI-DrugBank.d499.s16|26-30|sites|group
DDI-DrugBank.d499.s16|80-81|GI|brand
DDI-DrugBank.d499.s16|110-119|ketoprofen|drug
DDI-DrugBank.d499.s17|49-58|hemostasis|group
DDI-DrugBank.d499.s17|64-73|ketoprofen|drug
DDI-DrugBank.d499.s17|142-151|ketoprofen|drug
DDI-DrugBank.d499.s17|166-173|requires|group
DDI-DrugBank.d499.s17|195-202|patients|group
DDI-DrugBank.d499.s17|212-216|drugs|group
DDI-DrugBank.d499.s19|12-21|Probenecid|brand
DDI-DrugBank.d499.s19|23-31|increases|group
DDI-DrugBank.d499.s19|53-62|ketoprofen|drug
DDI-DrugBank.d499.s19|100-109|ketoprofen|drug
DDI-DrugBank.d499.s20|30-39|ketoprofen|drug
DDI-DrugBank.d499.s22|14-23|Ketoprofen|drug
DDI-DrugBank.d499.s22|37-42|NSAIDs|group
DDI-DrugBank.d499.s22|55-61|changes|group
DDI-DrugBank.d499.s22|124-129|levels|group
DDI-DrugBank.d499.s24|9-20|Nonsteroidal|brand
DDI-DrugBank.d499.s24|22-38|anti-inflammatory|group
DDI-DrugBank.d499.s24|40-45|agents|group
DDI-DrugBank.d499.s24|105-110|levels|group
DDI-DrugBank.d499.s25|38-43|levels|group
DDI-DrugBank.d499.s25|63-72|ketoprofen|drug
DDI-DrugBank.d499.s26|16-19|TEST|brand
DDI-DrugBank.d499.s26|21-32|INTERACTIONS|brand
DDI-DrugBank.d499.s26|35-40|EFFECT|brand
DDI-DrugBank.d499.s26|45-49|BLOOD|brand
DDI-DrugBank.d499.s26|51-61|COAGULATION|brand
DDI-DrugBank.d499.s26|63-72|Ketoprofen|drug
DDI-DrugBank.d499.s26|74-82|decreases|group
DDI-DrugBank.d499.s27|64-70|minutes|group
DDI-DrugBank.d499.s27|86-91|values|group
DDI-MedLine.d100.s0|29-36|blockers|group
DDI-MedLine.d100.s0|63-78|arachidonic acid|drug
DDI-MedLine.d100.s1|51-66|arachidonic acid|drug
DDI-MedLine.d100.s1|93-99|factors|group
DDI-MedLine.d100.s1|104-113|hemostasis|group
DDI-MedLine.d100.s2|58-61|ions|group
DDI-MedLine.d100.s2|133-140|contents|group
DDI-MedLine.d100.s3|11-26|arachidonic acid|drug
DDI-MedLine.d100.s3|42-54|phospholipids|group
DDI-MedLine.d100.s3|78-86|synthesis|group
DDI-MedLine.d100.s3|131-132|A2|brand
DDI-MedLine.d100.s3|176-179|ions|group
DDI-MedLine.d100.s4|41-48|controls|group
DDI-MedLine.d100.s4|50-55|levels|group
DDI-MedLine.d100.s4|73-76|ions|group
DDI-MedLine.d100.s4|81-89|platelets|group
DDI-MedLine.d100.s4|95-103|regulates|group
DDI-MedLine.d100.s4|123-131|reactions|group
DDI-MedLine.d100.s5|21-28|blockers|group
DDI-MedLine.d100.s5|64-73|nifedipine|drug
DDI-MedLine.d100.s6|6-11|agents|group
DDI-MedLine.d100.s6|90-91|A2|brand
DDI-MedLine.d100.s7|43-50|blockers|group
DDI-MedLine.d100.s7|105-117|antiaggregant|group
DDI-MedLine.d100.s8|6-12|effects|group
DDI-MedLine.d100.s8|25-32|blockers|group
DDI-MedLine.d100.s8|59-74|arachidonic acid|drug
DDI-MedLine.d100.s8|133-140|patients|group
DDI-DrugBank.d545.s0|47-52|levels|group
DDI-DrugBank.d259.s0|8-19|interactions|group
DDI-DrugBank.d323.s0|21-27|MYOBLOC|brand
DDI-DrugBank.d323.s0|33-47|aminoglycosides|group
DDI-DrugBank.d323.s0|58-63|agents|group
DDI-DrugBank.d323.s0|128-136|compounds|group
DDI-DrugBank.d323.s1|59-67|serotypes|group
DDI-DrugBank.d323.s1|96-99|less|group
DDI-DrugBank.d323.s1|108-113|months|group
DDI-DrugBank.d323.s2|23-31|paralysis|group
DDI-DrugBank.d323.s2|132-140|serotypes|group
DDI-DrugBank.d456.s0|46-57|ketoconazole|drug
DDI-DrugBank.d456.s0|59-67|increases|group
DDI-DrugBank.d456.s0|69-77|erlotinib|drug
DDI-DrugBank.d456.s0|79-81|AUC|brand
DDI-DrugBank.d456.s1|52-58|TARCEVA|brand
DDI-DrugBank.d456.s1|65-76|ketoconazole|drug
DDI-DrugBank.d456.s1|102-111|inhibitors|group
DDI-DrugBank.d456.s1|118-119|as|group
DDI-DrugBank.d456.s1|142-151|atazanavir|drug
DDI-DrugBank.d456.s1|154-167|clarithromycin|drug
DDI-DrugBank.d456.s1|170-178|indinavir|drug
DDI-DrugBank.d456.s1|181-192|itraconazole|drug
DDI-DrugBank.d456.s1|195-204|nefazodone|drug
DDI-DrugBank.d456.s1|207-216|nelfinavir|drug
DDI-DrugBank.d456.s1|219-227|ritonavir|drug
DDI-DrugBank.d456.s1|230-239|saquinavir|drug
DDI-DrugBank.d456.s1|242-254|telithromycin|drug
DDI-DrugBank.d456.s1|257-270|troleandomycin|drug
DDI-DrugBank.d456.s1|283-294|voriconazole|drug
DDI-DrugBank.d456.s2|59-67|erlotinib|drug
DDI-DrugBank.d456.s2|69-71|AUC|brand
DDI-DrugBank.d456.s3|10-19|treatments|group
DDI-DrugBank.d456.s4|46-52|TARCEVA|brand
DDI-DrugBank.d456.s4|104-108|NSCLC|brand
DDI-DrugBank.d456.s4|110-117|patients|group
DDI-DrugBank.d456.s4|177-184|patients|group
DDI-DrugBank.d456.s5|7-13|TARCEVA|brand
DDI-DrugBank.d456.s5|117-124|inducers|group
DDI-DrugBank.d456.s6|13-20|inducers|group
DDI-DrugBank.d456.s6|105-117|phenobarbital|drug
DDI-DrugBank.d456.s6|123-125|St.|brand
DDI-DrugBank.d456.s6|127-131|Johns|group
DDI-DrugBank.d456.s6|133-136|Wort|brand
DDI-DrugBank.d456.s7|15-26|Asymptomatic|brand
DDI-DrugBank.d456.s7|28-36|increases|group
DDI-DrugBank.d456.s7|47-59|transaminases|group
DDI-DrugBank.d456.s7|83-89|TARCEVA|brand
DDI-DrugBank.d456.s7|99-106|patients|group
DDI-DrugBank.d456.s8|43-56|(transaminases|group
DDI-DrugBank.d456.s9|34-40|TARCEVA|brand
DDI-DrugBank.d456.s9|66-72|changes|group
DDI-DrugBank.d456.s10|0-7|Patients|group
DDI-DrugBank.d456.s10|14-20|Hepatic|brand
DDI-DrugBank.d456.s10|22-31|Impairment|brand
DDI-DrugBank.d456.s10|76-84|erlotinib|drug
DDI-DrugBank.d456.s11|11-19|erlotinib|drug
DDI-DrugBank.d456.s11|50-57|patients|group
DDI-DrugBank.d456.s12|9-21|International|brand
DDI-DrugBank.d456.s12|23-32|Normalized|brand
DDI-DrugBank.d456.s12|34-38|Ratio|brand
DDI-DrugBank.d456.s12|44-52|Potential|brand
DDI-DrugBank.d456.s12|54-61|Bleeding|brand
DDI-DrugBank.d456.s12|63-75|International|brand
DDI-DrugBank.d456.s12|77-86|Normalized|brand
DDI-DrugBank.d456.s12|88-92|Ratio|brand
DDI-DrugBank.d456.s12|100-109|elevations|group
DDI-DrugBank.d456.s12|126-132|reports|group
DDI-DrugBank.d456.s12|146-151|events|group
DDI-DrugBank.d456.s12|205-213|bleedings|group
DDI-DrugBank.d456.s12|246-252|studies|group
DDI-DrugBank.d456.s13|0-7|Patients|group
DDI-DrugBank.d456.s13|54-67|anticoagulants|group
DDI-DrugBank.d456.s13|103-109|changes|group
DDI-DrugBank.d456.s13|134-136|INR|brand
DDI-MedLine.d89.s0|49-59|alterations|group
DDI-MedLine.d89.s1|32-41|antibiotic|group
DDI-MedLine.d89.s1|75-84|infections|group
DDI-MedLine.d89.s1|110-118|organisms|group
DDI-MedLine.d89.s1|156-162|kidneys|group
DDI-MedLine.d89.s3|47-53|kidneys|group
DDI-MedLine.d89.s3|129-135|results|group
DDI-MedLine.d89.s3|159-173|characteristics|group
DDI-MedLine.d89.s3|186-193|diseases|group
DDI-MedLine.d89.s4|108-115|symptoms|group
DDI-MedLine.d89.s7|148-155|patients|group
DDI-DrugBank.d141.s0|18-22|Drugs|group
DDI-DrugBank.d141.s0|25-35|Fibric acid|drug
DDI-DrugBank.d141.s0|37-47|Derivatives|group
DDI-DrugBank.d141.s0|50-55|Niacin|brand
DDI-DrugBank.d141.s0|57-71|(Nicotinic acid|drug
DDI-DrugBank.d141.s0|74-85|Erythromycin|drug
DDI-DrugBank.d141.s0|88-92|Azole|brand
DDI-DrugBank.d141.s0|94-104|Antifungals|group
DDI-DrugBank.d141.s0|107-114|Skeletal|brand
DDI-DrugBank.d141.s0|116-121|Muscle|brand
DDI-DrugBank.d141.s1|28-36|Hydroxide|brand
DDI-DrugBank.d141.s1|40-51|Cerivastatin|drug
DDI-DrugBank.d141.s1|60-73|concentrations|group
DDI-DrugBank.d141.s2|12-23|Cerivastatin|drug
DDI-DrugBank.d141.s2|32-45|concentrations|group
DDI-DrugBank.d141.s3|87-102|pharmacokinetits|group
DDI-DrugBank.d141.s3|107-118|cerivastatin|drug
DDI-DrugBank.d141.s3|155-159|males|group
DDI-DrugBank.d141.s3|196-202|studies|group
DDI-DrugBank.d141.s4|57-68|cerivastatin|drug
DDI-DrugBank.d141.s4|113-121|decreases|group
DDI-DrugBank.d141.s4|144-146|AUC|brand
DDI-DrugBank.d141.s4|160-163|Cmax|brand
DDI-DrugBank.d141.s4|189-200|cerivastatin|drug
DDI-DrugBank.d141.s5|110-121|cerivastatin|drug
DDI-DrugBank.d141.s5|146-150|hours|group
DDI-DrugBank.d141.s5|210-221|cerivastatin|drug
DDI-DrugBank.d141.s5|223-225|AUC|brand
DDI-DrugBank.d141.s5|230-233|less|group
DDI-DrugBank.d141.s5|262-265|Cmax|brand
DDI-DrugBank.d141.s5|304-315|cerivastatin|drug
DDI-DrugBank.d141.s6|58-69|cerivastatin|drug
DDI-DrugBank.d141.s6|213-224|cerivastatin|drug
DDI-DrugBank.d141.s7|9-14|Plasma|brand
DDI-DrugBank.d141.s7|24-29|levels|group
DDI-DrugBank.d141.s7|118-129|cerivastatin|drug
DDI-DrugBank.d141.s8|0-11|Cerivastatin|drug
DDI-DrugBank.d141.s8|20-33|concentrations|group
DDI-DrugBank.d141.s9|10-12|Co-|brand
DDI-DrugBank.d141.s9|45-56|cerivastatin|drug
DDI-DrugBank.d141.s9|69-78|volunteers|group
DDI-DrugBank.d141.s9|102-108|changes|group
DDI-DrugBank.d141.s9|149-151|VII|brand
DDI-DrugBank.d141.s10|4-6|AUC|brand
DDI-DrugBank.d141.s10|12-15|Cmax|brand
DDI-DrugBank.d141.s10|41-47|isomers|group
DDI-DrugBank.d141.s10|108-119|cerivastatin|drug
DDI-DrugBank.d141.s11|34-45|cerivastatin|drug
DDI-DrugBank.d141.s11|65-80|pharmacokinetics|group
DDI-DrugBank.d141.s11|85-96|cerivastatin|drug
DDI-DrugBank.d141.s12|17-36|hypercholesterolemic|drug
DDI-DrugBank.d141.s12|38-45|patients|group
DDI-DrugBank.d141.s12|61-72|cerivastatin|drug
DDI-DrugBank.d141.s12|74-76|AUC|brand
DDI-DrugBank.d141.s12|82-85|Cmax|brand
DDI-DrugBank.d141.s12|145-148|days|group
DDI-DrugBank.d141.s12|176-187|erythromycin|drug
DDI-DrugBank.d141.s13|6-16|CONCOMITANT|brand
DDI-DrugBank.d141.s13|18-24|THERAPY|brand
DDI-DrugBank.d141.s13|27-34|Although|brand
DDI-DrugBank.d141.s13|57-63|studies|group
DDI-DrugBank.d141.s13|97-103|studies|group
DDI-DrugBank.d141.s13|106-117|cerivastatin|drug
DDI-DrugBank.d141.s13|191-200|inhibitors|group
DDI-DrugBank.d141.s13|203-214|betablockers|group
DDI-DrugBank.d141.s13|233-240|blockers|group
DDI-DrugBank.d141.s13|243-251|diuretics|group
DDI-DrugBank.d141.s13|271-287|anti-inflammatory|group
DDI-DrugBank.d141.s13|289-293|drugs|group
DDI-DrugBank.d141.s13|295-301|(NSAIDs|group
DDI-DrugBank.d141.s13|355-366|interactions|group
DDI-DrugBank.d218.s0|47-53|studies|group
DDI-DrugBank.d218.s0|80-86|SYNAREL|brand
DDI-DrugBank.d218.s1|110-114|P-450|brand
DDI-DrugBank.d218.s1|116-122|enzymes|group
DDI-DrugBank.d218.s1|172-179|proteins|group
DDI-DrugBank.d218.s1|186-186|C|brand
DDI-DrugBank.d218.s1|194-205|interactions|group
DDI-DrugBank.d164.s0|20-26|studies|group
DDI-DrugBank.d164.s1|23-29|studies|group
DDI-DrugBank.d17.s0|0-13|Anticoagulants|group
DDI-DrugBank.d17.s1|0-7|(Effects|group
DDI-DrugBank.d17.s1|54-61|thiazide|drug
DDI-DrugBank.d17.s1|63-71|diuretics|group
DDI-DrugBank.d17.s2|7-17|adjustments|group
DDI-DrugBank.d17.s3|0-7|Antigout|group
DDI-DrugBank.d17.s3|9-19|medications|group
DDI-DrugBank.d17.s4|10-18|diuretics|group
DDI-DrugBank.d17.s4|49-57|uric acid|drug
DDI-DrugBank.d17.s5|21-28|antigout|group
DDI-DrugBank.d17.s5|30-40|medications|group
DDI-DrugBank.d17.s6|0-15|Antihypertensive|group
DDI-DrugBank.d17.s6|17-27|medications|group
DDI-DrugBank.d17.s6|91-96|agents|group
DDI-DrugBank.d17.s6|133-141|relaxants|group
DDI-DrugBank.d17.s7|0-7|(Effects|group
DDI-DrugBank.d17.s7|56-63|thiazide|drug
DDI-DrugBank.d17.s7|65-73|diuretics|group
DDI-DrugBank.d17.s8|7-17|adjustments|group
DDI-DrugBank.d17.s9|13-13|B|brand
DDI-DrugBank.d17.s9|18-32|Corticosteroids|group
DDI-DrugBank.d17.s9|37-49|Corticotropin|brand
DDI-DrugBank.d17.s10|21-28|thiazide|drug
DDI-DrugBank.d17.s10|30-38|diuretics|group
DDI-DrugBank.d17.s11|8-17|glycosides|group
DDI-DrugBank.d17.s12|21-28|thiazide|drug
DDI-DrugBank.d17.s12|30-38|diuretics|group
DDI-DrugBank.d17.s12|71-79|digitalis|group
DDI-DrugBank.d17.s14|48-55|thiazide|drug
DDI-DrugBank.d17.s14|57-65|diuretics|group
DDI-DrugBank.d17.s15|34-38|hours|group
DDI-DrugBank.d17.s16|0-12|Hypoglycemics|group
DDI-DrugBank.d17.s17|10-18|diuretics|group
DDI-DrugBank.d17.s17|44-49|levels|group
DDI-DrugBank.d17.s18|16-24|diabetics|group
DDI-DrugBank.d17.s18|61-71|medications|group
DDI-DrugBank.d17.s18|107-114|thiazide|drug
DDI-DrugBank.d17.s19|8-19|requirements|group
DDI-DrugBank.d17.s20|8-12|salts|group
DDI-DrugBank.d17.s21|21-28|thiazide|drug
DDI-DrugBank.d17.s21|30-38|diuretics|group
DDI-DrugBank.d17.s23|0-13|(Effectiveness|group
DDI-DrugBank.d17.s23|60-67|thiazide|drug
DDI-DrugBank.d17.s23|69-77|diuretics|group
DDI-DrugBank.d17.s24|13-29|anti-inflammatory|group
DDI-DrugBank.d17.s24|31-36|agents|group
DDI-DrugBank.d17.s25|9-16|patients|group
DDI-DrugBank.d17.s25|33-49|anti-inflammatory|group
DDI-DrugBank.d17.s25|99-114|antihypertensive|group
DDI-DrugBank.d17.s25|116-122|effects|group
DDI-DrugBank.d17.s25|143-149|sparing|drug
DDI-DrugBank.d17.s25|156-163|thiazide|drug
DDI-DrugBank.d17.s25|165-173|diuretics|group
DDI-DrugBank.d17.s26|16-33|hydroflumethiazide|drug
DDI-DrugBank.d17.s26|52-68|anti-inflammatory|group
DDI-DrugBank.d17.s26|70-75|agents|group
DDI-DrugBank.d17.s28|0-9|(Thiazides|group
DDI-DrugBank.d17.s28|33-46|responsiveness|group
DDI-DrugBank.d17.s29|46-58|effectiveness|group
DDI-DrugBank.d17.s31|10-14|drugs|group
DDI-DrugBank.d17.s31|33-46|responsiveness|group
DDI-DrugBank.d17.s32|11-22|INTERFERENCE|brand
DDI-DrugBank.d17.s32|50-56|effects|group
DDI-DrugBank.d17.s32|59-63|Blood|brand
DDI-DrugBank.d17.s32|83-88|levels|group
DDI-DrugBank.d17.s32|107-114|patients|group
DDI-DrugBank.d17.s32|123-136|predisposition|drug
DDI-DrugBank.d17.s32|167-171|Serum|brand
DDI-DrugBank.d17.s32|183-188|levels|group
DDI-DrugBank.d17.s32|233-237|Serum|brand
DDI-DrugBank.d17.s32|247-252|levels|group
DDI-DrugBank.d17.s32|254-262|(thiazide|drug
DDI-DrugBank.d17.s32|264-272|diuretics|group
DDI-DrugBank.d17.s32|325-329|tests|group
DDI-DrugBank.d17.s32|352-356|Serum|brand
DDI-DrugBank.d17.s32|358-366|uric acid|drug
DDI-DrugBank.d17.s32|368-373|levels|group
DDI-DrugBank.d17.s32|394-398|Serum|brand
DDI-DrugBank.d17.s32|433-438|levels|group
DDI-DrugBank.d17.s33|16-21|levels|group
DDI-DrugBank.d17.s33|46-53|patients|group
DDI-DrugBank.d17.s33|56-60|Serum|brand
DDI-DrugBank.d17.s33|89-94|levels|group
DDI-DrugBank.d17.s33|115-123|Thiazides|group
DDI-DrugBank.d17.s33|168-172|tests|group
DDI-DrugBank.d207.s0|0-9|Substances|group
DDI-DrugBank.d207.s0|20-27|inducers|group
DDI-DrugBank.d207.s0|75-83|gefitinib|drug
DDI-DrugBank.d207.s0|109-122|concentrations|group
DDI-DrugBank.d207.s1|3-10|patients|group
DDI-DrugBank.d207.s1|214-219|events|group
DDI-DrugBank.d207.s1|256-263|CLINICAL|brand
DDI-DrugBank.d207.s1|265-303|PHARMACOLOGY-Pharmacokinetics-Drug-Drug|brand
DDI-DrugBank.d207.s1|305-316|Interactions|group
DDI-DrugBank.d207.s1|322-327|DOSAGE|brand
DDI-DrugBank.d207.s1|333-353|ADMINISTRATION-Dosage|brand
DDI-DrugBank.d207.s1|355-364|Adjustment|brand
DDI-DrugBank.d207.s1|366-373|sections|group
DDI-DrugBank.d207.s2|14-23|Normalized|brand
DDI-DrugBank.d207.s2|25-29|Ratio|brand
DDI-DrugBank.d207.s2|37-46|elevations|group
DDI-DrugBank.d207.s2|64-69|events|group
DDI-DrugBank.d207.s2|98-105|patients|group
DDI-DrugBank.d207.s2|132-137|IRESSA|brand
DDI-DrugBank.d207.s3|0-7|Patients|group
DDI-DrugBank.d207.s3|59-65|changes|group
DDI-DrugBank.d207.s3|90-92|INR|brand
DDI-DrugBank.d207.s4|0-9|Substances|group
DDI-DrugBank.d207.s4|27-36|inhibitors|group
DDI-DrugBank.d207.s4|62-73|ketoconazole|drug
DDI-DrugBank.d207.s4|79-90|itraconazole|drug
DDI-DrugBank.d207.s4|102-110|gefitinib|drug
DDI-DrugBank.d207.s4|136-144|gefitinib|drug
DDI-DrugBank.d207.s4|153-166|concentrations|group
DDI-DrugBank.d207.s5|52-62|experiences|group
DDI-DrugBank.d207.s6|60-69|inhibitors|group
DDI-DrugBank.d207.s6|76-81|IRESSA|brand
DDI-DrugBank.d207.s7|0-4|Drugs|group
DDI-DrugBank.d207.s7|74-84|H2-receptor|brand
DDI-DrugBank.d207.s7|86-96|antagonists|group
DDI-DrugBank.d207.s7|150-163|concentrations|group
DDI-DrugBank.d207.s7|168-173|IRESSA|brand
DDI-DrugBank.d207.s8|6-7|II|brand
DDI-DrugBank.d207.s8|36-41|IRESSA|brand
DDI-DrugBank.d207.s8|103-108|IRESSA|brand
DDI-DrugBank.d115.s0|0-4|Drugs|group
DDI-DrugBank.d115.s0|21-28|imatinib|drug
DDI-DrugBank.d115.s0|37-50|concentrations|group
DDI-DrugBank.d115.s0|52-56|Drugs|group
DDI-DrugBank.d115.s0|76-83|imatinib|drug
DDI-DrugBank.d115.s0|92-105|concentrations|group
DDI-DrugBank.d115.s0|108-114|Caution|brand
DDI-DrugBank.d115.s0|150-156|Gleevec|brand
DDI-DrugBank.d115.s0|163-172|inhibitors|group
DDI-DrugBank.d115.s0|202-213|ketoconazole|drug
DDI-DrugBank.d115.s0|216-227|itraconazole|drug
DDI-DrugBank.d115.s0|230-241|erythromycin|drug
DDI-DrugBank.d115.s0|244-257|clarithromycin|drug
DDI-DrugBank.d115.s1|0-9|Substances|group
DDI-DrugBank.d115.s1|109-116|imatinib|drug
DDI-DrugBank.d115.s1|118-131|concentrations|group
DDI-DrugBank.d115.s2|47-54|imatinib|drug
DDI-DrugBank.d115.s2|61-67|Gleevec|brand
DDI-DrugBank.d115.s2|92-103|ketoconazole|drug
DDI-DrugBank.d115.s3|0-4|Drugs|group
DDI-DrugBank.d115.s3|24-31|imatinib|drug
DDI-DrugBank.d115.s3|40-53|concentrations|group
DDI-DrugBank.d115.s3|56-65|Substances|group
DDI-DrugBank.d115.s3|76-83|inducers|group
DDI-DrugBank.d115.s3|141-148|imatinib|drug
DDI-DrugBank.d115.s3|157-170|concentrations|group
DDI-DrugBank.d115.s4|0-13|Co-medications|group
DDI-DrugBank.d115.s4|41-53|dexamethasone|drug
DDI-DrugBank.d115.s4|92-104|phenobarbital|drug
DDI-DrugBank.d115.s4|109-110|St|brand
DDI-DrugBank.d115.s5|0-4|Johns|group
DDI-DrugBank.d115.s5|6-9|Wort|brand
DDI-DrugBank.d115.s5|49-55|Gleevec|brand
DDI-DrugBank.d115.s6|24-33|volunteers|group
DDI-DrugBank.d115.s6|49-53|doses|group
DDI-DrugBank.d115.s6|96-102|Gleevec|brand
DDI-DrugBank.d115.s6|115-121|Gleevec|brand
DDI-DrugBank.d115.s6|209-215|AUC(0-8|brand
DDI-DrugBank.d115.s7|3-10|patients|group
DDI-DrugBank.d115.s7|43-50|inducers|group
DDI-DrugBank.d115.s7|91-96|agents|group
DDI-DrugBank.d115.s7|103-106|less|group
DDI-DrugBank.d115.s8|0-4|Drugs|group
DDI-DrugBank.d115.s8|58-64|Gleevec|brand
DDI-DrugBank.d115.s8|66-72|Gleevec|brand
DDI-DrugBank.d115.s8|74-82|increases|group
DDI-DrugBank.d115.s8|102-104|AUC|brand
DDI-DrugBank.d115.s8|109-119|simvastatin|drug
DDI-DrugBank.d115.s8|213-219|Gleevec|brand
DDI-DrugBank.d115.s9|53-59|Gleevec|brand
DDI-DrugBank.d115.s9|73-82|substrates|group
DDI-DrugBank.d115.s10|70-74|drugs|group
DDI-DrugBank.d115.s10|83-106|triazolo-benzodiazepines|group
DDI-DrugBank.d115.s10|141-148|blockers|group
DDI-DrugBank.d115.s10|159-165|HMG-CoA|brand
DDI-DrugBank.d115.s10|177-186|inhibitors|group
DDI-DrugBank.d115.s11|35-40|CYP2C9|brand
DDI-DrugBank.d115.s11|54-61|patients|group
DDI-DrugBank.d115.s11|75-89|anticoagulation|group
DDI-DrugBank.d115.s11|139-145|heparin|drug
DDI-DrugBank.d115.s12|10-16|Gleevec|brand
DDI-DrugBank.d115.s12|18-25|inhibits|group
DDI-DrugBank.d115.s12|57-62|CYP2D6|brand
DDI-DrugBank.d115.s12|84-97|concentrations|group
DDI-DrugBank.d115.s13|21-30|substrates|group
DDI-DrugBank.d115.s13|35-40|CYP2D6|brand
DDI-DrugBank.d115.s13|95-101|Gleevec|brand
DDI-DrugBank.d115.s14|12-18|studies|group
DDI-DrugBank.d115.s15|10-16|Gleevec|brand
DDI-DrugBank.d115.s15|18-25|inhibits|group
DDI-DrugBank.d115.s15|41-57|O-glucuronidation|brand
DDI-DrugBank.d115.s15|78-78|M|brand
DDI-DrugBank.d115.s15|96-101|levels|group
DDI-DrugBank.d115.s16|88-94|Gleevec|brand
DDI-DrugBank.d115.s17|12-18|studies|group
DDI-DrugBank.d115.s17|23-28|humans|group
DDI-DrugBank.d221.s0|44-52|NovoSeven|brand
DDI-DrugBank.d221.s0|77-88|concentrates|group
DDI-DrugBank.d221.s0|151-157|studies|group
DDI-DrugBank.d221.s1|0-11|Simultaneous|group
DDI-DrugBank.d221.s1|50-61|concentrates|group
DDI-DrugBank.d221.s1|86-97|concentrates|group
DDI-DrugBank.d221.s2|105-112|episodes|group
DDI-DrugBank.d221.s2|136-151|antifibrinolytic|group
DDI-DrugBank.d221.s2|153-161|therapies|group
DDI-DrugBank.d221.s2|170-184|tranexamic acid|drug
DDI-DrugBank.d221.s2|187-203|aminocaproic acid|drug
DDI-DrugBank.d221.s2|210-218|NovoSeven|brand
DDI-DrugBank.d221.s3|44-52|solutions|group
DDI-DrugBank.d109.s0|0-24|Ketoconazole/Itraconazole|drug
DDI-DrugBank.d109.s0|27-36|Macrolides|group
DDI-DrugBank.d109.s0|39-47|Including|brand
DDI-DrugBank.d109.s0|49-60|Erythromycin|drug
DDI-DrugBank.d553.s0|5-14|Laboratory|brand
DDI-DrugBank.d553.s0|16-19|Test|brand
DDI-DrugBank.d553.s0|21-32|Interactions|group
DDI-DrugBank.d553.s0|35-46|Prolongation|brand
DDI-DrugBank.d553.s0|103-112|continuous|group
DDI-DrugBank.d553.s0|114-124|intravenous|group
DDI-DrugBank.d553.s0|138-143|AMICAR|brand
DDI-DrugBank.d553.s0|148-154|dosages|group
DDI-DrugBank.d553.s1|18-24|studies|group
DDI-DrugBank.d553.s1|35-42|patients|group
DDI-DrugBank.d553.s2|18-24|studies|group
DDI-DrugBank.d553.s2|50-63|concentrations|group
DDI-DrugBank.d553.s2|104-107|EACA|brand
DDI-DrugBank.d553.s2|109-116|inhibits|group
DDI-DrugBank.d553.s2|118-120|ADP|brand
DDI-DrugBank.d553.s2|180-182|ATP|brand
DDI-DrugBank.d553.s2|236-244|platelets|group
DDI-DrugBank.d553.s3|17-21|bolus|group
DDI-DrugBank.d553.s3|26-31|AMICAR|brand
DDI-DrugBank.d553.s3|56-69|concentrations|group
DDI-DrugBank.d553.s4|21-26|AMICAR|brand
DDI-DrugBank.d553.s4|64-75|fibrinolysis|group
DDI-DrugBank.d553.s5|24-28|bolus|group
DDI-DrugBank.d553.s5|91-96|levels|group
DDI-DrugBank.d553.s6|0-3|Thus|group
DDI-DrugBank.d553.s6|6-19|concentrations|group
DDI-DrugBank.d553.s6|68-75|patients|group
DDI-DrugBank.d553.s6|145-158|concentrations|group
DDI-DrugBank.d553.s6|176-188|abnormalities|group
DDI-DrugBank.d553.s6|211-215|tests|group
DDI-DrugBank.d553.s7|23-36|concentrations|group
DDI-DrugBank.d553.s7|41-46|AMICAR|brand
DDI-DrugBank.d553.s7|61-68|patients|group
DDI-DrugBank.d227.s0|11-21|potentiates|group
DDI-DrugBank.d227.s0|64-72|relaxants|group
DDI-DrugBank.d227.s0|111-119|relaxants|group
DDI-DrugBank.d227.s0|126-128|MAC|brand
DDI-DrugBank.d227.s0|207-207|N|brand
DDI-DrugBank.d227.s1|4-11|CLINICAL|brand
DDI-DrugBank.d227.s1|13-24|PHARMACOLOGY|brand
DDI-DrugBank.d420.s0|0-7|Antacids|group
DDI-DrugBank.d420.s0|46-56|Concomitant|brand
DDI-DrugBank.d420.s0|83-90|cefdinir|drug
DDI-DrugBank.d420.s0|92-99|capsules|group
DDI-DrugBank.d420.s0|112-117|Maalox|brand
DDI-DrugBank.d420.s0|119-120|TC|brand
DDI-DrugBank.d420.s0|133-139|reduces|group
DDI-DrugBank.d420.s1|14-17|Cmax|brand
DDI-DrugBank.d420.s2|25-31|effects|group
DDI-DrugBank.d420.s2|36-43|cefdinir|drug
DDI-DrugBank.d420.s2|45-60|pharmacokinetics|group
DDI-DrugBank.d420.s2|95-99|hours|group
DDI-DrugBank.d420.s2|113-117|hours|group
DDI-DrugBank.d420.s2|125-132|cefdinir|drug
DDI-DrugBank.d420.s3|3-10|antacids|group
DDI-DrugBank.d420.s3|32-38|OMNICEF|brand
DDI-DrugBank.d420.s3|49-55|OMNICEF|brand
DDI-DrugBank.d420.s3|84-88|hours|group
DDI-DrugBank.d420.s4|35-45|antibiotics|group
DDI-DrugBank.d420.s4|59-66|inhibits|group
DDI-DrugBank.d420.s4|91-98|cefdinir|drug
DDI-DrugBank.d420.s4|141-144|A.C.|brand
DDI-DrugBank.d420.s4|169-176|cefdinir|drug
DDI-DrugBank.d420.s4|185-190|levels|group
DDI-DrugBank.d420.s5|5-15|Supplements|group
DDI-DrugBank.d420.s5|21-25|Foods|group
DDI-DrugBank.d420.s5|27-35|Fortified|brand
DDI-DrugBank.d420.s5|42-45|Iron|brand
DDI-DrugBank.d420.s5|47-57|Concomitant|brand
DDI-DrugBank.d420.s5|77-84|cefdinir|drug
DDI-DrugBank.d420.s5|105-108|iron|drug_n
DDI-DrugBank.d420.s5|151-154|iron|drug_n
DDI-DrugBank.d420.s5|156-158|(as|group
DDI-DrugBank.d420.s5|160-164|FeSO4|brand
DDI-DrugBank.d420.s5|170-177|vitamins|group
DDI-DrugBank.d420.s5|216-219|iron|drug_n
DDI-DrugBank.d420.s6|3-6|iron|drug_n
DDI-DrugBank.d420.s6|8-18|supplements|group
DDI-DrugBank.d420.s6|40-46|OMNICEF|brand
DDI-DrugBank.d420.s6|57-63|OMNICEF|brand
DDI-DrugBank.d420.s6|92-96|hours|group
DDI-DrugBank.d420.s7|14-18|foods|group
DDI-DrugBank.d420.s7|52-55|iron|drug_n
DDI-DrugBank.d420.s7|68-81|iron-fortified|drug_n
DDI-DrugBank.d420.s7|93-99|cereals|group
DDI-DrugBank.d420.s7|105-112|cefdinir|drug
DDI-DrugBank.d420.s8|27-40|iron-fortified|drug_n
DDI-DrugBank.d420.s8|75-80|iron/6|drug_n
DDI-DrugBank.d420.s8|115-122|cefdinir|drug
DDI-DrugBank.d420.s8|124-139|pharmacokinetics|group
DDI-DrugBank.d420.s9|11-17|OMNICEF|brand
DDI-DrugBank.d420.s9|23-26|Oral|brand
DDI-DrugBank.d420.s9|28-37|Suspension|brand
DDI-DrugBank.d420.s9|64-77|iron-fortified|drug_n
DDI-DrugBank.d420.s10|21-27|reports|group
DDI-DrugBank.d420.s10|40-45|stools|group
DDI-DrugBank.d420.s10|50-57|patients|group
DDI-DrugBank.d420.s10|77-84|cefdinir|drug
DDI-DrugBank.d420.s10|89-93|Japan|brand
DDI-DrugBank.d420.s11|77-84|cefdinir|drug
DDI-DrugBank.d420.s11|103-110|products|group
DDI-DrugBank.d420.s11|116-119|iron|drug_n
DDI-DrugBank.d420.s12|16-19|Test|brand
DDI-DrugBank.d420.s12|21-32|Interactions|group
DDI-DrugBank.d420.s12|64-70|ketones|group
DDI-DrugBank.d420.s12|100-104|tests|group
DDI-DrugBank.d420.s13|22-29|cefdinir|drug
DDI-DrugBank.d420.s13|98-106|Clinitest|brand
DDI-DrugBank.d420.s13|110-117|Benedict|brand
DDI-DrugBank.d420.s13|134-141|Fehlings|group
DDI-DrugBank.d420.s14|31-35|tests|group
DDI-DrugBank.d420.s14|72-80|reactions|group
DDI-DrugBank.d420.s14|91-99|Clinistix|brand
DDI-DrugBank.d420.s14|105-112|Tes-Tape|brand
DDI-DrugBank.d420.s15|0-13|Cephalosporins|group
DDI-DrugBank.d420.s15|66-71|Coombs|group
DDI-MedLine.d8.s0|21-28|KRM-1648|brand
DDI-MedLine.d8.s0|68-76|ofloxacin|drug
DDI-MedLine.d8.s0|87-99|Mycobacterium|brand
DDI-MedLine.d8.s0|101-108|ulcerans|group
DDI-MedLine.d8.s1|4-16|antimicrobial|group
DDI-MedLine.d8.s1|30-49|benzoxazinorifamycin|drug
DDI-MedLine.d8.s1|52-59|KRM-1648|brand
DDI-MedLine.d8.s1|98-106|ofloxacin|drug
DDI-MedLine.d8.s1|149-155|strains|group
DDI-MedLine.d8.s1|174-181|isolates|group
DDI-MedLine.d8.s1|186-198|Mycobacterium|brand
DDI-MedLine.d8.s1|200-207|ulcerans|group
DDI-MedLine.d8.s2|10-10|M|brand
DDI-MedLine.d8.s3|0-7|ulcerans|group
DDI-MedLine.d8.s3|31-36|counts|group
DDI-MedLine.d8.s3|46-51|BACTEC|brand
DDI-MedLine.d8.s4|86-93|KRM-1648|brand
DDI-MedLine.d8.s4|103-103|M|brand
DDI-MedLine.d8.s5|0-7|ulcerans|group
DDI-MedLine.d8.s5|63-68|values|group
DDI-MedLine.d8.s6|19-27|ofloxacin|drug
DDI-MedLine.d8.s6|30-37|KRM-1648|brand
DDI-MedLine.d8.s6|97-103|effects|group
DDI-MedLine.d8.s6|173-181|ofloxacin|drug
DDI-MedLine.d8.s7|6-12|results|group
DDI-MedLine.d8.s7|27-34|KRM-1648|brand
DDI-MedLine.d8.s7|78-78|M|brand
DDI-MedLine.d8.s8|0-7|ulcerans|group
DDI-MedLine.d22.s0|9-16|promotes|group
DDI-MedLine.d22.s0|134-141|enhances|group
DDI-MedLine.d22.s0|147-153|effects|group
DDI-MedLine.d22.s3|108-120|effectiveness|group
DDI-MedLine.d22.s4|41-47|becomes|group
DDI-MedLine.d22.s4|78-85|combines|group
DDI-MedLine.d22.s4|92-100|membranes|group
DDI-MedLine.d22.s4|111-120|polyamines|group
DDI-MedLine.d22.s5|42-46|acids|group
DDI-MedLine.d22.s5|59-63|cells|group
DDI-MedLine.d22.s5|112-120|synthesis|group
DDI-MedLine.d22.s5|166-170|acids|group
DDI-MedLine.d42.s0|0-9|Sildenafil|drug
DDI-MedLine.d42.s1|12-16|Since|brand
DDI-MedLine.d42.s1|38-39|US|brand
DDI-MedLine.d42.s1|41-44|Food|brand
DDI-MedLine.d42.s1|50-53|Drug|brand
DDI-MedLine.d42.s1|55-68|Administration|brand
DDI-MedLine.d42.s1|73-77|March|brand
DDI-MedLine.d42.s1|85-94|sildenafil|drug
DDI-MedLine.d42.s1|121-128|millions|group
DDI-MedLine.d42.s2|7-13|studies|group
DDI-MedLine.d42.s2|19-27|consensus|group
DDI-MedLine.d42.s2|29-35|reports|group
DDI-MedLine.d42.s2|94-110|contraindications|group
DDI-MedLine.d42.s2|122-133|interactions|group
DDI-MedLine.d42.s3|22-28|reviews|group
DDI-MedLine.d42.s3|37-43|studies|group
DDI-MedLine.d42.s3|64-73|sildenafil|drug
DDI-MedLine.d42.s3|88-94|effects|group
DDI-MedLine.d42.s3|105-116|interactions|group
DDI-MedLine.d42.s3|137-143|factors|group
DDI-MedLine.d42.s3|173-177|focus|group
DDI-MedLine.d42.s3|199-209|populations|group
DDI-MedLine.d42.s3|229-236|diabetes|group
DDI-MedLine.d42.s3|238-245|mellitus|group
DDI-MedLine.d42.s3|284-291|injuries|group
DDI-MedLine.d42.s3|305-313|disorders|group
DDI-MedLine.d42.s4|9-16|Clinical|brand
DDI-MedLine.d42.s4|18-24|studies|group
DDI-MedLine.d42.s4|32-38|reports|group
DDI-MedLine.d42.s4|45-56|commentaries|group
DDI-MedLine.d42.s4|62-71|editorials|group
DDI-MedLine.d42.s4|84-93|sildenafil|drug
DDI-MedLine.d42.s4|145-151|January|brand
DDI-MedLine.d42.s4|162-167|August|brand
DDI-MedLine.d42.s4|198-205|searches|group
DDI-MedLine.d42.s4|210-216|MEDLINE|brand
DDI-MedLine.d42.s4|219-228|PREMEDLINE|brand
DDI-MedLine.d42.s4|235-247|International|brand
DDI-MedLine.d42.s4|249-262|Pharmaceutical|brand
DDI-MedLine.d42.s4|264-272|Abstracts|group
DDI-MedLine.d42.s4|285-289|terms|group
DDI-MedLine.d42.s4|291-300|sildenafil|drug
DDI-MedLine.d42.s4|303-308|Viagra|brand
DDI-MedLine.d42.s5|9-18|Sildenafil|drug
DDI-MedLine.d42.s5|37-49|effectiveness|group
DDI-MedLine.d42.s5|134-141|diabetes|group
DDI-MedLine.d42.s5|143-150|mellitus|group
DDI-MedLine.d42.s5|172-180|disorders|group
DDI-MedLine.d42.s5|234-243|inhibitors|group
DDI-MedLine.d42.s6|85-99|SSRI-associated|brand
DDI-MedLine.d42.s7|5-13|disorders|group
DDI-MedLine.d42.s7|105-114|sildenafil|drug
DDI-MedLine.d42.s8|27-36|sildenafil|drug
DDI-MedLine.d42.s9|9-16|patients|group
DDI-MedLine.d42.s9|135-141|serious|group
DDI-MedLine.d42.s9|166-172|effects|group
DDI-MedLine.d42.s9|179-188|sildenafil|drug
DDI-MedLine.d42.s10|13-20|patients|group
DDI-MedLine.d42.s10|29-33|drugs|group
DDI-MedLine.d42.s10|87-97|metabolizes|group
DDI-MedLine.d42.s10|99-108|sildenafil|drug
DDI-MedLine.d42.s10|141-154|concentrations|group
DDI-MedLine.d42.s10|190-194|doses|group
DDI-MedLine.d42.s10|199-208|sildenafil|drug
DDI-MedLine.d42.s11|13-22|Sildenafil|drug
DDI-MedLine.d42.s12|57-70|considerations|group
DDI-MedLine.d42.s12|114-119|access|group
DDI-MedLine.d42.s12|140-147|pathways|group
DDI-DrugBank.d46.s0|38-42|drugs|group
DDI-DrugBank.d46.s0|62-69|thiazide|drug
DDI-DrugBank.d46.s0|71-79|diuretics|group
DDI-DrugBank.d46.s1|2-8|Alcohol|brand
DDI-DrugBank.d46.s1|11-22|barbiturates|group
DDI-DrugBank.d46.s1|28-36|narcotics|group
DDI-DrugBank.d46.s1|39-50|Potentiation|brand
DDI-DrugBank.d46.s3|2-13|Antidiabetic|group
DDI-DrugBank.d46.s3|15-19|drugs|group
DDI-DrugBank.d46.s3|28-33|agents|group
DDI-DrugBank.d46.s3|48-53|Dosage|brand
DDI-DrugBank.d46.s3|73-84|antidiabetic|group
DDI-DrugBank.d46.s5|8-23|antihypertensive|group
DDI-DrugBank.d46.s5|25-29|drugs|group
DDI-DrugBank.d46.s5|32-39|Additive|brand
DDI-DrugBank.d46.s7|2-15|Cholestyramine|brand
DDI-DrugBank.d46.s7|32-37|resins|group
DDI-DrugBank.d46.s7|40-53|Cholestytamine|brand
DDI-DrugBank.d46.s7|70-75|resins|group
DDI-DrugBank.d46.s7|107-114|thiazide|drug
DDI-DrugBank.d46.s7|116-124|diuretics|group
DDI-DrugBank.d46.s9|2-16|Corticosteroids|group
DDI-DrugBank.d46.s9|19-22|ACTH|brand
DDI-DrugBank.d46.s9|25-35|Intensified|brand
DDI-DrugBank.d46.s11|2-8|Pressor|brand
DDI-DrugBank.d46.s11|10-15|amines|group
DDI-DrugBank.d46.s11|41-48|Possible|brand
DDI-DrugBank.d46.s11|80-85|amines|group
DDI-DrugBank.d46.s13|2-9|Skeletal|brand
DDI-DrugBank.d46.s13|18-26|relaxants|group
DDI-DrugBank.d46.s13|67-74|Possible|brand
DDI-DrugBank.d46.s13|86-99|responsiveness|group
DDI-DrugBank.d46.s15|2-8|Lithium|brand
DDI-DrugBank.d46.s15|11-19|Generally|brand
DDI-DrugBank.d46.s15|46-54|diuretics|group
DDI-DrugBank.d46.s16|9-14|agents|group
DDI-DrugBank.d46.s17|40-51|preparations|group
DDI-DrugBank.d46.s17|72-83|preparations|group
DDI-DrugBank.d46.s17|90-103|chlorothiazide|drug
DDI-DrugBank.d46.s19|2-14|Non-steroidal|brand
DDI-DrugBank.d46.s19|16-32|Anti-inflammatory|group
DDI-DrugBank.d46.s19|34-38|Drugs|group
DDI-DrugBank.d46.s19|49-56|patients|group
DDI-DrugBank.d46.s19|97-113|anti-inflammatory|group
DDI-DrugBank.d46.s19|163-178|antihypertensive|group
DDI-DrugBank.d46.s19|180-186|effects|group
DDI-DrugBank.d46.s19|197-213|potassium-sparing|drug
DDI-DrugBank.d46.s19|219-226|thiazide|drug
DDI-DrugBank.d46.s19|228-236|diuretics|group
DDI-DrugBank.d46.s20|16-29|chlorothiazide|drug
DDI-DrugBank.d46.s20|49-65|anti-inflammatory|group
DDI-DrugBank.d46.s20|67-72|agents|group
DDI-DrugBank.d46.s22|2-16|Drug/Laboratory|brand
DDI-DrugBank.d46.s22|18-21|Test|brand
DDI-DrugBank.d46.s22|23-34|Interactions|group
DDI-DrugBank.d46.s22|37-45|Thiazides|group
DDI-DrugBank.d46.s22|90-94|tests|group
DDI-DrugBank.d389.s0|0-13|Antihistamines|group
DDI-DrugBank.d389.s0|31-37|effects|group
DDI-DrugBank.d389.s0|52-66|antidepressants|group
DDI-DrugBank.d389.s0|69-80|barbiturates|group
DDI-DrugBank.d389.s0|102-104|CNS|brand
DDI-DrugBank.d389.s0|106-116|depressants|group
DDI-DrugBank.d389.s1|4-13|inhibitors|group
DDI-DrugBank.d389.s1|41-55|anticholinergic|group
DDI-DrugBank.d389.s1|57-63|effects|group
DDI-DrugBank.d389.s1|68-81|antihistamines|group
DDI-DrugBank.d389.s2|16-21|amines|group
DDI-DrugBank.d389.s2|38-53|antihypertensive|group
DDI-DrugBank.d389.s2|55-61|effects|group
DDI-DrugBank.d389.s2|86-94|alkaloids|group
DDI-DrugBank.d389.s3|0-6|Effects|group
DDI-DrugBank.d389.s3|11-26|sympathomimetics|group
DDI-DrugBank.d389.s3|47-49|MAO|brand
DDI-DrugBank.d389.s3|51-60|inhibitors|group
DDI-DrugBank.d389.s3|66-69|beta|group
DDI-DrugBank.d389.s3|82-89|blockers|group
DDI-MedLine.d77.s0|0-6|Effects|group
DDI-MedLine.d77.s0|15-26|temperatures|group
DDI-MedLine.d77.s0|31-42|microtubules|group
DDI-MedLine.d77.s0|66-70|axons|group
DDI-MedLine.d77.s0|103-108|nerves|group
DDI-MedLine.d77.s1|26-32|changes|group
DDI-MedLine.d77.s1|51-62|microtubules|group
DDI-MedLine.d77.s1|82-86|axons|group
DDI-MedLine.d77.s1|159-170|preparations|group
DDI-MedLine.d77.s1|185-191|various|group
DDI-MedLine.d77.s1|193-204|temperatures|group
DDI-MedLine.d77.s1|209-214|Eagles|group
DDI-MedLine.d77.s2|6-12|degrees|group
DDI-MedLine.d77.s2|14-14|C|brand
DDI-MedLine.d77.s2|35-39|axons|group
DDI-MedLine.d77.s2|56-59|plus|group
DDI-MedLine.d77.s2|64-68|minus|group
DDI-MedLine.d77.s2|74-78|S.E.M|brand
DDI-MedLine.d77.s3|5-16|microtubules|group
DDI-MedLine.d77.s4|22-28|degrees|group
DDI-MedLine.d77.s4|30-30|C|brand
DDI-MedLine.d77.s4|64-67|plus|group
DDI-MedLine.d77.s4|72-76|minus|group
DDI-MedLine.d77.s4|82-86|S.E.M|brand
DDI-MedLine.d77.s5|28-33|levels|group
DDI-MedLine.d77.s5|44-49|nerves|group
DDI-MedLine.d77.s6|5-8|loss|group
DDI-MedLine.d77.s6|13-24|microtubules|group
DDI-MedLine.d77.s6|41-46|nerves|group
DDI-MedLine.d77.s6|96-102|process|group
DDI-MedLine.d77.s7|77-85|synthesis|group
DDI-MedLine.d77.s8|24-35|microtubules|group
DDI-MedLine.d77.s8|55-57|D2O|brand
DDI-MedLine.d77.s9|9-20|microtubules|group
DDI-MedLine.d77.s9|130-137|vesicles|group
DDI-MedLine.d77.s9|149-153|axons|group
DDI-DrugBank.d111.s0|14-16|MAO|brand
DDI-DrugBank.d111.s0|18-27|inhibitors|group
DDI-DrugBank.d111.s0|55-61|sulfate|drug
DDI-DrugBank.d111.s0|75-81|sulfate|drug
DDI-DrugBank.d111.s0|98-100|HC1|brand
DDI-DrugBank.d111.s0|103-113|Concomitant|brand
DDI-DrugBank.d111.s0|122-131|L-tyrosine|brand
DDI-DrugBank.d111.s0|151-153|MAO|brand
DDI-DrugBank.d111.s0|155-164|inhibitors|group
DDI-DrugBank.d485.s0|19-27|Substrate|brand
DDI-DrugBank.d485.s1|0-7|Inhibits|group
DDI-DrugBank.d485.s1|9-14|CYP1A2|brand
DDI-DrugBank.d485.s2|15-17|May|brand
DDI-DrugBank.d485.s2|62-70|estrogens|group
DDI-DrugBank.d485.s3|21-34|contraceptives|group
DDI-DrugBank.d485.s4|0-8|Acitretin|drug
DDI-DrugBank.d485.s4|11-20|Interferes|group
DDI-DrugBank.d485.s4|96-107|preparations|group
DDI-DrugBank.d485.s5|35-48|contraceptives|group
DDI-DrugBank.d485.s5|55-62|implants|group
DDI-DrugBank.d485.s5|65-75|injectables|group
DDI-DrugBank.d485.s6|19-21|May|brand
DDI-DrugBank.d485.s6|32-34|CYP|brand
DDI-DrugBank.d485.s6|50-59|progestins|group
DDI-DrugBank.d485.s6|107-119|effectiveness|group
DDI-DrugBank.d485.s8|0-10|Antibiotics|group
DDI-DrugBank.d485.s8|40-48|Pregnancy|brand
DDI-DrugBank.d485.s8|120-126|studies|group
DDI-DrugBank.d485.s8|154-160|effects|group
DDI-DrugBank.d485.s8|173-183|antibiotics|group
DDI-DrugBank.d485.s8|195-208|concentrations|group
DDI-DrugBank.d485.s8|223-230|steroids|group
DDI-DrugBank.d485.s10|0-13|Anticoagulants|group
DDI-DrugBank.d485.s10|16-26|Combination|brand
DDI-DrugBank.d485.s10|37-50|contraceptives|group
DDI-DrugBank.d485.s10|81-87|effects|group
DDI-DrugBank.d485.s10|101-111|derivatives|group
DDI-DrugBank.d485.s11|21-34|contraceptives|group
DDI-DrugBank.d485.s11|77-85|disorders|group
DDI-DrugBank.d485.s12|0-14|Anticonvulsants|group
DDI-DrugBank.d485.s12|43-55|phenobarbital|drug
DDI-DrugBank.d485.s12|82-89|Increase|brand
DDI-DrugBank.d485.s12|139-148|progestins|group
DDI-DrugBank.d485.s12|197-209|effectiveness|group
DDI-DrugBank.d485.s14|0-12|Ascorbic acid|drug
DDI-DrugBank.d485.s14|15-19|Doses|group
DDI-DrugBank.d485.s14|24-36|ascorbic acid|drug
DDI-DrugBank.d485.s14|47-47|C|brand
DDI-DrugBank.d485.s14|123-131|estrogens|group
DDI-DrugBank.d485.s15|9-20|implications|group
DDI-DrugBank.d485.s16|0-11|Atorvastatin|drug
DDI-DrugBank.d485.s16|14-25|Atorvastatin|drug
DDI-DrugBank.d485.s16|27-35|increases|group
DDI-DrugBank.d485.s16|41-43|AUC|brand
DDI-DrugBank.d485.s17|0-14|Benzodiazepines|group
DDI-DrugBank.d485.s17|17-27|Combination|brand
DDI-DrugBank.d485.s17|38-51|contraceptives|group
DDI-DrugBank.d485.s17|88-102|benzodiazepines|group
DDI-DrugBank.d485.s17|104-114|(alprazolam|drug
DDI-DrugBank.d485.s17|135-142|diazepam|drug
DDI-DrugBank.d485.s17|175-180|others|group
DDI-DrugBank.d485.s17|182-191|(lorazepam|drug
DDI-DrugBank.d485.s17|194-201|oxazepam|drug
DDI-DrugBank.d485.s17|204-212|temazepam|drug
DDI-DrugBank.d485.s18|0-13|Clofibric acid|drug
DDI-DrugBank.d485.s18|16-26|Combination|brand
DDI-DrugBank.d485.s18|37-50|contraceptives|group
DDI-DrugBank.d485.s18|82-95|clofibric acid|drug
DDI-DrugBank.d485.s19|14-24|Combination|brand
DDI-DrugBank.d485.s19|35-48|contraceptives|group
DDI-DrugBank.d485.s19|122-135|concentrations|group
DDI-DrugBank.d485.s20|21-26|levels|group
DDI-DrugBank.d485.s21|7-14|inducers|group
DDI-DrugBank.d485.s21|24-31|inducers|group
DDI-DrugBank.d485.s21|50-63|levels/effects|group
DDI-DrugBank.d485.s22|8-15|inducers|group
DDI-DrugBank.d485.s22|70-79|nevirapine|drug
DDI-DrugBank.d485.s22|82-94|phenobarbital|drug
DDI-DrugBank.d485.s22|112-121|rifamycins|drug
DDI-DrugBank.d485.s23|14-25|Griseofulvin|brand
DDI-DrugBank.d485.s23|77-90|contraceptives|group
DDI-DrugBank.d485.s23|110-116|changes|group
DDI-DrugBank.d485.s24|0-10|pregnancies|group
DDI-DrugBank.d485.s26|10-20|Combination|brand
DDI-DrugBank.d485.s26|31-44|contraceptives|group
DDI-DrugBank.d485.s27|37-46|inhibitors|group
DDI-DrugBank.d485.s27|48-54|(NNRTIs|group
DDI-DrugBank.d485.s27|58-67|Nevirapine|drug
DDI-DrugBank.d485.s27|89-94|levels|group
DDI-DrugBank.d485.s27|120-133|contraceptives|group
DDI-DrugBank.d485.s29|12-22|delavirdine|drug
DDI-DrugBank.d485.s30|20-28|efavirenz|drug
DDI-DrugBank.d485.s31|0-11|Prednisolone|drug
DDI-DrugBank.d485.s31|14-20|Ethinyl|brand
DDI-DrugBank.d485.s31|62-73|prednisolone|drug
DDI-DrugBank.d485.s31|104-117|concentrations|group
DDI-DrugBank.d485.s32|9-18|inhibitors|group
DDI-DrugBank.d485.s32|21-30|Amprenavir|drug
DDI-DrugBank.d485.s32|33-41|lopinavir|drug
DDI-DrugBank.d485.s32|44-53|nelfinavir|drug
DDI-DrugBank.d485.s32|60-68|ritonavir|drug
DDI-DrugBank.d485.s32|105-110|levels|group
DDI-DrugBank.d485.s32|136-149|contraceptives|group
DDI-DrugBank.d485.s34|0-8|Indinavir|drug
DDI-DrugBank.d485.s34|44-49|levels|group
DDI-DrugBank.d485.s34|75-88|contraceptives|group
DDI-DrugBank.d485.s35|12-21|saquinavir|drug
DDI-DrugBank.d485.s36|10-17|Rifampin|brand
DDI-DrugBank.d485.s36|19-27|increases|group
DDI-DrugBank.d485.s36|74-83|progestins|group
DDI-DrugBank.d485.s36|138-150|effectiveness|group
DDI-DrugBank.d485.s36|176-189|irregularities|group
DDI-DrugBank.d485.s38|0-13|Salicylic acid|drug
DDI-DrugBank.d485.s38|16-26|Combination|brand
DDI-DrugBank.d485.s38|37-50|contraceptives|group
DDI-DrugBank.d485.s38|82-95|salicylic acid|drug
DDI-DrugBank.d485.s39|12-22|Combination|brand
DDI-DrugBank.d485.s39|33-46|contraceptives|group
DDI-DrugBank.d485.s40|0-11|Theophylline|drug
DDI-DrugBank.d485.s40|14-20|Ethinyl|brand
DDI-DrugBank.d485.s40|62-73|theophylline|drug
DDI-DrugBank.d485.s40|104-117|concentrations|group
DDI-DrugBank.d485.s41|10-24|antidepressants|group
DDI-DrugBank.d485.s41|26-39|(amitriptyline|drug
DDI-DrugBank.d485.s41|42-51|imipramine|drug
DDI-DrugBank.d485.s41|54-66|nortriptyline|drug
DDI-DrugBank.d485.s41|70-79|Metabolism|brand
DDI-DrugBank.d485.s41|122-135|contraceptives|group
DDI-DrugBank.d485.s41|156-161|levels|group
DDI-DrugBank.d485.s41|166-179|antidepressant|group
DDI-DrugBank.d485.s43|10-18|NUTRITION|brand
DDI-DrugBank.d485.s43|22-25|HERB|brand
DDI-DrugBank.d485.s43|27-38|INTERACTIONS|brand
DDI-DrugBank.d485.s43|41-44|Food|brand
DDI-DrugBank.d485.s43|47-49|CNS|brand
DDI-DrugBank.d485.s43|51-57|effects|group
DDI-DrugBank.d485.s43|111-124|contraceptives|group
DDI-DrugBank.d485.s44|17-25|increases|group
DDI-DrugBank.d485.s44|45-58|concentrations|group
DDI-DrugBank.d485.s44|113-118|levels|group
DDI-DrugBank.d485.s45|9-20|implications|group
DDI-DrugBank.d485.s46|20-21|St|brand
DDI-DrugBank.d485.s46|23-27|Johns|group
DDI-DrugBank.d485.s46|51-63|effectiveness|group
DDI-DrugBank.d485.s46|89-102|contraceptives|group
DDI-DrugBank.d485.s46|124-130|enzymes|group
DDI-MedLine.d94.s0|48-52|sites|group
DDI-MedLine.d94.s2|135-148|concentrations|group
DDI-MedLine.d94.s2|191-199|membranes|group
DDI-MedLine.d94.s4|8-22|beta-adrenergic|group
DDI-MedLine.d94.s4|38-44|defects|group
DDI-MedLine.d94.s5|49-54|occurs|group
DDI-MedLine.d94.s7|78-79|Hz|brand
DDI-MedLine.d94.s7|85-91|degrees|group
DDI-MedLine.d94.s7|93-93|C|brand
DDI-MedLine.d94.s7|122-133|preparations|group
DDI-MedLine.d94.s7|159-167|membranes|group
DDI-MedLine.d94.s9|4-16|effectiveness|group
DDI-MedLine.d94.s10|68-73|hearts|group
DDI-MedLine.d94.s10|80-83|York|brand
DDI-MedLine.d94.s10|85-89|Heart|brand
DDI-MedLine.d94.s10|91-101|Association|brand
DDI-MedLine.d94.s10|114-118|class|group
DDI-MedLine.d94.s10|120-121|IV|brand
DDI-MedLine.d94.s10|143-156|concentrations|group
DDI-MedLine.d94.s11|4-7|EC50|brand
DDI-MedLine.d94.s11|9-14|values|group
DDI-MedLine.d94.s11|130-136|classes|group
DDI-MedLine.d94.s11|138-139|II|brand
DDI-MedLine.d94.s11|144-146|III|brand
DDI-MedLine.d94.s11|152-153|IV|brand
DDI-MedLine.d94.s12|11-20|inhibitors|group
DDI-MedLine.d94.s12|22-28|cocaine|drug
DDI-MedLine.d94.s12|34-44|desipramine|drug
DDI-MedLine.d94.s12|97-103|effects|group
DDI-MedLine.d94.s12|181-185|class|group
DDI-MedLine.d94.s12|187-188|IV|brand
DDI-MedLine.d94.s13|20-30|experiments|group
DDI-MedLine.d94.s13|189-195|classes|group
DDI-MedLine.d94.s13|197-198|II|brand
DDI-MedLine.d94.s13|203-205|III|brand
DDI-MedLine.d94.s13|211-212|IV|brand
DDI-MedLine.d94.s13|225-230|versus|group
DDI-MedLine.d94.s15|73-79|nervous|group
DDI-MedLine.d94.s16|56-62|effects|group
DDI-MedLine.d94.s16|83-88|agents|group
DDI-MedLine.d94.s16|99-105|cocaine|drug
DDI-MedLine.d94.s16|111-121|desipramine|drug
DDI-MedLine.d94.s17|50-54|class|group
DDI-MedLine.d94.s17|56-57|IV|brand
DDI-MedLine.d94.s17|90-96|cocaine|drug
DDI-MedLine.d94.s17|102-112|desipramine|drug
DDI-MedLine.d94.s18|21-32|consequences|group
DDI-MedLine.d94.s18|97-108|predisposing|drug
DDI-MedLine.d78.s0|4-19|fluoroquinolones|drug
DDI-MedLine.d78.s0|39-48|infections|group
DDI-MedLine.d78.s1|4-19|fluoroquinolones|drug
DDI-MedLine.d78.s1|43-47|class|group
DDI-MedLine.d78.s1|52-62|antibiotics|group
DDI-MedLine.d78.s2|6-11|agents|group
DDI-MedLine.d78.s2|24-34|norfloxacin|drug
DDI-MedLine.d78.s2|37-49|ciprofloxacin|drug
DDI-MedLine.d78.s2|52-60|ofloxacin|drug
DDI-MedLine.d78.s2|77-88|lomefloxacin|drug
DDI-MedLine.d78.s2|163-170|profiles|group
DDI-MedLine.d78.s2|213-218|agents|group
DDI-MedLine.d78.s2|284-293|infections|group
DDI-MedLine.d78.s2|299-309|prostatitis|group
DDI-MedLine.d78.s3|0-9|Advantages|group
DDI-MedLine.d78.s3|27-31|class|group
DDI-MedLine.d78.s3|36-46|antibiotics|group
DDI-MedLine.d78.s3|64-79|pharmacokinetics|group
DDI-MedLine.d78.s3|82-94|effectiveness|group
DDI-MedLine.d78.s3|124-132|organisms|group
DDI-MedLine.d78.s3|180-190|antibiotics|group
DDI-MedLine.d78.s4|4-19|fluoroquinolones|drug
DDI-DrugBank.d53.s0|21-30|nelfinavir|drug
DDI-DrugBank.d53.s0|70-81|azithromycin|drug
DDI-DrugBank.d53.s1|21-30|nelfinavir|drug
DDI-DrugBank.d53.s1|70-81|azithromycin|drug
DDI-DrugBank.d53.s1|95-101|tablets|group
DDI-DrugBank.d53.s1|104-110|results|group
DDI-DrugBank.d53.s1|125-136|azithromycin|drug
DDI-DrugBank.d53.s1|144-157|concentrations|group
DDI-DrugBank.d53.s2|30-41|azithromycin|drug
DDI-DrugBank.d53.s2|100-109|nelfinavir|drug
DDI-DrugBank.d53.s2|144-150|effects|group
DDI-DrugBank.d53.s2|155-166|azithromycin|drug
DDI-DrugBank.d53.s2|190-202|abnormalities|group
DDI-DrugBank.d53.s3|0-11|Azithromycin|drug
DDI-DrugBank.d53.s4|34-41|dictates|group
DDI-DrugBank.d53.s4|89-96|patients|group
DDI-DrugBank.d53.s4|111-122|azithromycin|drug
DDI-DrugBank.d53.s5|18-27|macrolides|group
DDI-DrugBank.d53.s5|98-110|anticoagulant|group
DDI-DrugBank.d53.s5|112-118|effects|group
DDI-DrugBank.d53.s6|17-23|studies|group
DDI-DrugBank.d53.s6|45-56|azithromycin|drug
DDI-DrugBank.d53.s6|68-72|drugs|group
DDI-DrugBank.d53.s7|25-29|doses|group
DDI-DrugBank.d53.s7|32-43|azithromycin|drug
DDI-DrugBank.d53.s7|72-87|pharmacokinetics|group
DDI-DrugBank.d53.s7|92-103|atorvastatin|drug
DDI-DrugBank.d53.s7|145-153|efavirenz|drug
DDI-DrugBank.d53.s7|156-166|fluconazole|drug
DDI-DrugBank.d53.s7|169-177|indinavir|drug
DDI-DrugBank.d53.s7|180-188|midazolam|drug
DDI-DrugBank.d53.s7|202-211|sildenafil|drug
DDI-DrugBank.d53.s7|214-225|theophylline|drug
DDI-DrugBank.d53.s7|227-238|(intravenous|group
DDI-DrugBank.d53.s7|251-259|triazolam|drug
DDI-DrugBank.d53.s7|262-290|trimethoprim/sulfamethoxazole|drug
DDI-DrugBank.d53.s7|295-304|zidovudine|drug
DDI-DrugBank.d53.s8|23-31|efavirenz|drug
DDI-DrugBank.d53.s8|36-46|fluconazole|drug
DDI-DrugBank.d53.s8|75-90|pharmacokinetics|group
DDI-DrugBank.d53.s8|95-106|azithromycin|drug
DDI-DrugBank.d53.s9|56-67|azithromycin|drug
DDI-DrugBank.d53.s9|110-115|agents|group
DDI-DrugBank.d53.s10|0-11|Interactions|group
DDI-DrugBank.d53.s10|22-26|drugs|group
DDI-DrugBank.d53.s10|76-81|trials|group
DDI-DrugBank.d53.s10|88-99|azithromycin|drug
DDI-DrugBank.d53.s11|38-44|studies|group
DDI-DrugBank.d53.s12|0-10|Nonetheless|group
DDI-DrugBank.d53.s12|52-59|products|group
DDI-DrugBank.d53.s13|48-59|interactions|group
DDI-DrugBank.d53.s13|66-77|azithromycin|drug
DDI-DrugBank.d53.s13|89-93|drugs|group
DDI-DrugBank.d53.s13|141-148|patients|group
DDI-DrugBank.d53.s13|162-168|Digoxin|brand
DDI-DrugBank.d53.s13|187-200|concentrations|group
DDI-DrugBank.d53.s15|14-25|hexobarbital|drug
DDI-DrugBank.d53.s15|41-54|concentrations|group
DDI-DrugBank.d53.s16|11-14|Test|brand
DDI-DrugBank.d53.s16|16-27|Interactions|group
DDI-DrugBank.d53.s16|67-78|interactions|group
DDI-DrugBank.d53.s17|7-15|Treatment|brand
DDI-DrugBank.d53.s17|17-23|Studies|group
DDI-DrugBank.d53.s17|56-62|courses|group
DDI-DrugBank.d53.s17|67-70|Zmax|brand
DDI-DrugBank.d200.s0|37-45|acyclovir|drug
DDI-DrugBank.d200.s2|13-19|effects|group
DDI-DrugBank.d80.s0|15-26|interactions|group
DDI-DrugBank.d80.s0|36-41|Mentax|brand
DDI-DrugBank.d80.s0|55-57|HCl|brand
DDI-DrugBank.d80.s0|66-70|Cream|brand
DDI-DrugBank.d80.s0|87-91|drugs|group
DDI-DrugBank.d551.s0|60-66|studies|group
DDI-DrugBank.d551.s1|84-93|lovastatin|drug
DDI-DrugBank.d551.s1|96-105|metoprolol|drug
DDI-DrugBank.d551.s1|119-131|valproic acid|drug
DDI-DrugBank.d551.s2|23-26|Cmax|brand
DDI-DrugBank.d551.s2|32-34|AUC|brand
DDI-DrugBank.d551.s2|74-75|SR|brand
DDI-DrugBank.d551.s4|12-18|studies|group
DDI-DrugBank.d551.s4|41-47|WelChol|brand
DDI-DrugBank.d551.s4|55-66|atorvastatin|drug
DDI-DrugBank.d551.s4|69-78|lovastatin|drug
DDI-DrugBank.d551.s4|84-94|simvastatin|drug
DDI-DrugBank.d551.s4|154-160|HMG-CoA|brand
DDI-DrugBank.d551.s5|6-10|drugs|group
DDI-DrugBank.d551.s6|25-29|drugs|group
DDI-DrugBank.d551.s6|41-51|alterations|group
DDI-DrugBank.d551.s6|62-67|levels|group
DDI-DrugBank.d551.s6|135-144|physicians|group
DDI-DrugBank.d551.s6|178-183|levels|group
DDI-DrugBank.d551.s6|188-194|effects|group
DDI-DrugBank.d335.s0|3-10|TRANXENE|brand
DDI-DrugBank.d335.s0|41-45|drugs|group
DDI-DrugBank.d335.s0|69-75|nervous|group
DDI-DrugBank.d335.s0|150-155|agents|group
DDI-DrugBank.d335.s1|18-26|indicates|group
DDI-DrugBank.d335.s1|57-64|prolongs|group
DDI-DrugBank.d335.s1|90-101|hexobarbital|drug
DDI-DrugBank.d335.s1|127-135|increases|group
DDI-DrugBank.d335.s1|152-158|effects|group
DDI-DrugBank.d335.s2|9-15|studies|group
DDI-DrugBank.d335.s2|72-82|medications|group
DDI-DrugBank.d335.s3|4-10|actions|group
DDI-DrugBank.d335.s3|19-33|benzodiazepines|group
DDI-DrugBank.d335.s3|57-68|barbiturates|group
DDI-DrugBank.d335.s3|71-79|narcotics|group
DDI-DrugBank.d335.s3|82-95|phenothiazines|group
DDI-DrugBank.d335.s3|116-125|inhibitors|group
DDI-DrugBank.d335.s3|136-150|antidepressants|group
DDI-DrugBank.d335.s4|3-10|TRANXENE|brand
DDI-DrugBank.d335.s4|12-18|tablets|group
DDI-DrugBank.d335.s4|78-83|states|group
DDI-DrugBank.d335.s5|19-25|studies|group
DDI-DrugBank.d335.s5|39-46|subjects|group
DDI-DrugBank.d335.s5|82-89|antacids|group
DDI-DrugBank.d335.s5|106-111|levels|group
DDI-DrugBank.d335.s5|168-175|TRANXENE|brand
DDI-DrugBank.d335.s5|177-183|tablets|group
DDI-DrugBank.d375.s0|23-34|interactions|group
DDI-DrugBank.d375.s0|41-47|EMTRIVA|brand
DDI-DrugBank.d375.s0|86-94|indinavir|drug
DDI-DrugBank.d375.s0|97-105|stavudine|drug
DDI-DrugBank.d375.s0|108-118|famciclovir|drug
DDI-DrugBank.d375.s0|125-133|tenofovir|drug
DDI-DrugBank.d375.s1|42-53|interactions|group
DDI-DrugBank.d375.s1|72-76|drugs|group
DDI-DrugBank.d122.s0|73-86|cephalosporins|drug
DDI-DrugBank.d122.s0|108-118|antibiotics|group
DDI-DrugBank.d122.s0|130-138|diuretics|group
DDI-DrugBank.d122.s0|148-157|furosemide|drug
DDI-DrugBank.d122.s1|67-73|dosages|group
DDI-DrugBank.d122.s1|82-96|aminoglycosides|group
DDI-DrugBank.d122.s1|224-234|antibiotics|group
DDI-DrugBank.d122.s2|51-61|ceftazidime|drug
DDI-DrugBank.d122.s2|91-96|trials|group
DDI-DrugBank.d122.s3|53-63|beta-lactam|group
DDI-DrugBank.d122.s3|65-75|antibiotics|group
DDI-DrugBank.d122.s3|88-98|ceftazidime|drug
DDI-DrugBank.d122.s3|119-125|studies|group
DDI-DrugBank.d122.s3|141-146|curves|group
DDI-DrugBank.d122.s5|16-19|Test|brand
DDI-DrugBank.d122.s5|21-32|Interactions|group
DDI-DrugBank.d122.s5|56-66|ceftazidime|drug
DDI-DrugBank.d122.s5|144-152|CLINITEST|brand
DDI-DrugBank.d122.s5|155-161|tablets|group
DDI-DrugBank.d122.s5|164-172|Benedicts|group
DDI-DrugBank.d122.s5|187-194|Fehlings|group
DDI-DrugBank.d122.s6|31-35|tests|group
DDI-DrugBank.d122.s6|72-80|reactions|group
DDI-DrugBank.d122.s6|91-99|CLINISTIX|brand
DDI-DrugBank.d122.s6|105-112|TES-TAPE|brand
DDI-DrugBank.d436.s0|46-57|interactions|group
DDI-DrugBank.d523.s0|113-123|medications|group
DDI-DrugBank.d523.s0|128-134|predict|drug
DDI-DrugBank.d523.s0|155-166|interactions|group
DDI-DrugBank.d523.s1|0-11|Interactions|group
DDI-DrugBank.d523.s2|5-11|EFFECTS|brand
DDI-DrugBank.d523.s2|100-109|drowsiness|group
DDI-DrugBank.d523.s3|31-38|patients|group
DDI-DrugBank.d523.s3|51-60|drowsiness|group
DDI-DrugBank.d523.s3|110-116|tablets|group
DDI-DrugBank.d523.s4|21-29|reactions|group
DDI-DrugBank.d523.s4|35-43|dizziness|group
DDI-DrugBank.d523.s4|54-61|weakness|group
DDI-DrugBank.d523.s5|0-5|Others|group
DDI-DrugBank.d523.s5|17-32|Neuropsychiatric|brand
DDI-DrugBank.d523.s5|35-43|Confusion|brand
DDI-DrugBank.d523.s6|47-60|hallucinations|group
DDI-DrugBank.d523.s6|89-96|tinnitus|group
DDI-DrugBank.d523.s6|190-198|nystagmus|group
DDI-DrugBank.d523.s6|201-210|strabismus|group
DDI-DrugBank.d523.s6|213-218|miosis|group
DDI-DrugBank.d523.s6|221-229|mydriasis|group
DDI-DrugBank.d523.s7|16-26|Hypotension|brand
DDI-DrugBank.d523.s8|5-13|instances|group
DDI-DrugBank.d523.s9|18-23|Nausea|brand
DDI-DrugBank.d523.s11|15-21|Urinary|brand
DDI-DrugBank.d523.s12|13-20|enuresis|group
DDI-DrugBank.d523.s13|7-15|Instances|group
DDI-DrugBank.d523.s13|26-33|pruritus|group
DDI-DrugBank.d523.s14|12-14|CNS|brand
DDI-DrugBank.d523.s14|34-41|symptoms|group
DDI-DrugBank.d523.s15|25-29|tests|group
DDI-DrugBank.d523.s15|71-78|patients|group
DDI-DrugBank.d523.s15|110-113|SGOT|brand
DDI-DrugBank.d523.s16|41-49|KEMSTROTM|brand
DDI-DrugBank.d523.s16|90-96|tablets|group
